var title_f3_6_3168="Caustic stricture esophagus";
var content_f3_6_3168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Caustic strictures of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 17-year-old patient presented with recurrent dysphagia after ingesting an unknown quantity of pine oil solvent and sodium hydroxide six weeks prior. Endoscopic evaluation noted multiple strictures and edema. Inital direct laryngoscopy one day after ingestion was unremarkable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3168=[""].join("\n");
var outline_f3_6_3168=null;
var title_f3_6_3169="Optic disc swelling";
var content_f3_6_3169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc swelling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top: Fully developed optic disc swelling, in this case papilledema. Note the absence of distinct disc margins, obstruction of blood vessels as they cross the disc margin, hemorrhages, and cotton wool spots. The blood vessels change course abruptly as they approach the disc because they are running up and over the elevated disc substance. Bottom: Mild optic disc swelling. Note the concentric lines (Paton's lines) in the retina next to the disc (arrow). This occurs because the swollen disc pushes the retina aside.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3169=[""].join("\n");
var outline_f3_6_3169=null;
var title_f3_6_3170="Mitral annular dynamics";
var content_f3_6_3170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Mitral annular dynamics and corresponding tissue Doppler echocardiogram spectral display",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B show the movement of the mitral annulus during systole and diastole; panel C shows the corresponding pulsed-tissue Doppler echocardiogram spectral display.",
"    <div class=\"footnotes\">",
"     S: peak systolic velocity; E: peak early diastolic velocity; A: peak atrial velocity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3170=[""].join("\n");
var outline_f3_6_3170=null;
var title_f3_6_3171="VSD short axis color Doppler echo";
var content_f3_6_3171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/57768/shaxcvsd_conv.mp4?title=VSD+short+axis+color+Doppler+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram (short-axis view) of a membranous ventricular septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view from the 2-D echocardiogram with color flow Doppler shows a ventricular septal defect of the membranous part of the interventricular septum with shunting of blood primarily in systole and a smaller amount in diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3171=[""].join("\n");
var outline_f3_6_3171=null;
var title_f3_6_3172="Hyperthyroidism (overactive thyroid)";
var content_f3_6_3172=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/6/3172/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3172/contributors\" id=\"au5549\">",
"       Douglas S Ross, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/6/3172/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3172/contributors\" id=\"se4042\">",
"       David S Cooper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/6/3172/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3172/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/6/3172?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HYPERTHYROIDISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hyperthyroidism is the medical term for an overactive thyroid (hyper = excessive). In people with hyperthyroidism, the thyroid gland produces too much thyroid hormone. When this occurs, the body's metabolism is increased, which can cause a variety of symptoms.",
"    </p>",
"    <p>",
"     This topic discusses the symptoms, diagnostic tests, and treatment options for HYPERthyroidism. HYPOthyroidism is discussed in a separate topic. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS THE THYROID?",
"     </span>",
"    </p>",
"    <p>",
"     The thyroid is a butterfly-shaped gland in the middle of the neck, located below the larynx (voice box) and above the clavicles (collarbones) (",
"     <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"      figure 1",
"     </a>",
"     ). The thyroid produces two hormones, triiodothyronine (T3) and thyroxine (T4), that regulate how the body uses and stores energy (also known as the body's metabolism).",
"    </p>",
"    <p>",
"     The thyroid is controlled by a gland in the brain, known as the pituitary. The pituitary produces thyroid stimulating hormone (TSH), which stimulates the thyroid to produce T3 and T4.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HYPERTHYROIDISM CAUSES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Graves' disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Graves' disease is the most common cause of hyperthyroidism. It is not clear why Graves' disease develops in most people, although it more common in certain families.",
"    </p>",
"    <p>",
"     In people with Graves' disease, the immune system produces an antibody that stimulates the thyroid gland to produce too much thyroid hormone. This is most common in women between the ages of 20 and 40, but can occur at any age in men or women. The thyroid gland enlarges (called a goiter) (",
"     <a class=\"graphic graphic_figure graphicRef58509 \" href=\"UTD.htm?41/45/42704\">",
"      figure 2",
"     </a>",
"     ) and makes excessive amounts of thyroid hormone, causing symptoms of hyperthyroidism (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Hyperthyroidism symptoms'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Some people develop eye problems (called Graves' ophthalmopathy or orbitopathy), which causes dry, irritated or red eyes, and in severe cases may cause double vision. Others develop swelling behind or around the eyes that causes the eyes to bulge out, or inflammation of muscle in the eyelids that can cause excessive lid opening (",
"     <a class=\"graphic graphic_figure graphicRef58509 \" href=\"UTD.htm?41/45/42704\">",
"      figure 2",
"     </a>",
"     ). The more severe manifestations of Graves&rsquo; eye disease are uncommon, except in smokers. In its most severe form, people with Graves' ophthalmopathy can develop inflammation of the optic nerves, which can result in loss of vision.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Other causes",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One or more thyroid nodules (small growths or lumps in the thyroid gland) can produce too much thyroid hormone. The nodule is then called a hot nodule, toxic nodule, or when there is more than one, a toxic nodular goiter. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=see_link\">",
"        \"Patient information: Thyroid nodules (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Painless (\"silent or lymphocytic\") thyroiditis and postpartum thyroiditis are disorders in which the thyroid becomes temporarily inflamed and releases thyroid hormone into the bloodstream, causing hyperthyroidism.",
"       <br/>",
"       <br/>",
"       Postpartum thyroiditis can occur several months after delivery. The hyperthyroid symptoms may last for several months, often followed by several months of hypothyroid symptoms, such as fatigue, muscle cramps, bloating, and weight gain.",
"      </li>",
"      <li>",
"       Subacute (granulomatous) thyroiditis is thought to be caused by a virus. It causes a painful, tender, enlarged thyroid gland. The thyroid becomes inflamed and releases thyroid hormone into the blood stream; the hyperthyroidism resolves when the viral infection improves, and may also be followed by several months of hypothyroid symptoms.",
"      </li>",
"      <li>",
"       Taking too much thyroid hormone medication for hypothyroidism.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HYPERTHYROIDISM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with hyperthyroidism have symptoms, including one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Anxiety, irritability, trouble sleeping",
"      </li>",
"      <li>",
"       Weakness (in particular of the upper arms and thighs, making it difficult to lift heavy items or climb stairs or get up from a chair)",
"      </li>",
"      <li>",
"       Tremors (of the hands)",
"      </li>",
"      <li>",
"       Perspiring more than normal, difficulty tolerating hot weather",
"      </li>",
"      <li>",
"       Rapid, forceful, or irregular heartbeats",
"      </li>",
"      <li>",
"       Fatigue",
"      </li>",
"      <li>",
"       Weight loss in spite of a normal or increased appetite",
"      </li>",
"      <li>",
"       Frequent bowel movements",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, some women have irregular menstrual periods or stop having their periods altogether. This can be associated with infertility. Men may develop enlarged or tender breasts, or erectile dysfunction, which resolves when hyperthyroidism is treated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HYPERTHYROIDISM DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Hyperthyroidism can be diagnosed with blood tests that measure the amount of thyroid hormone and thyroid-stimulating hormone (TSH). Typically, the thyroid hormone level is high and the TSH level is low. A thyroid scan may also be recommended to help determine the cause of hyperthyroidism (Graves' disease, toxic nodular goiter, or thyroiditis).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      HYPERTHYROIDISM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Hyperthyroidism can be treated using medicine, radioiodine, or surgery. Many factors, such as your age and the severity and type of hyperthyroidism, as well as your preferences, are important in determining which treatment is best.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;The two main types of medicines used to treat hyperthyroidism are antithyroid drugs and beta-blockers. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"      \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Antithyroid drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antithyroid drugs, such as methimazole (MMI or Tapazole) and propylthiouracil (PTU), work by decreasing how much thyroid hormone the body makes. Both are very effective, but methimazole is preferred because of a greater risk of serious side effects with PTU. Carbimazole is similar to methimazole and is used in many countries, but not in the United States.",
"    </p>",
"    <p>",
"     Because methimazole can be associated with birth defects, for pregnant women, PTU is the preferred drug during the first trimester. After the first trimester, methimazole is preferred. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"      \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     These medications can be used:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       As a short-term (four to eight weeks) treatment in people with Graves' disease or toxic nodular goiter, before treatment with radioiodine or surgery.",
"      </li>",
"      <li>",
"       As a long-term (one to two years) treatment for Graves' disease. The disease goes into remission in about 30 percent of people and antithyroid drugs can be used to control hyperthyroidism while waiting to see if remission occurs.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     People who have very mild Graves' disease may have as high as a 50 to 70 percent chance of remission. It is possible to have a relapse years later, and most people will need to eventually consider permanent treatment with radioactive iodine or surgery.",
"    </p>",
"    <p>",
"     Antithyroid drugs have some minor side effects, such as rash, hives, painful joints, fever, and stomach upset. A more serious complication called agranulocytosis (lack of white blood cells) can occur, but this is very rare. Patients taking antithyroid drugs should notify their clinician immediately if they get a sore throat, fever, or any signs of a bacterial infection. PTU has rarely been linked with liver failure.",
"    </p>",
"    <p>",
"     While taking antithyroid drugs, you will have a blood test for thyroid hormone every four to six weeks until your hyperthyroidism is under control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Beta-blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beta-blockers, such as atenolol or propranolol, are often started as soon as the diagnosis of hyperthyroidism is made. While beta-blockers do not reduce thyroid hormone production, they can control many of the bothersome symptoms, such as rapid heart rate, tremors, anxiety, and heat intolerance. Once the hyperthyroidism is under control (with antithyroid drugs, surgery, or radioactive iodine), the beta-blocker is stopped.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Radioactive iodine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Destroying the thyroid with radioiodine, called ablation, is a permanent way to treat hyperthyroidism. The amount of radiation used is small and does not cause cancer, infertility, or birth defects. This is the most widely used treatment for hyperthyroidism in the United States.",
"    </p>",
"    <p>",
"     Radioiodine is given in liquid or capsule form, and it works by destroying much of the thyroid tissue. This takes about 6 to 18 weeks. People with severe symptoms, older adults, and people with heart problems should first be treated with an antithyroid drug to control symptoms. Most people who take radioiodine develop hypothyroidism and will need to take thyroid hormone supplements for the rest of their lives. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     As with most treatments, there are some risks with radioactive iodine:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Sometimes, after apparently successful treatment, the condition returns and further treatment is needed.",
"      </li>",
"      <li>",
"       About 10 to 20 percent of people who use radioiodine treatment require a second dose. These people usually have severe hyperthyroidism or a very large goiter.",
"      </li>",
"      <li>",
"       Occasionally, people with Graves' disease find that their eye symptoms worsen after therapy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     People who are treated with radioiodine should avoid close physical contact, especially with young children and pregnant women, for three to seven days after treatment because of the possibility of exposing them to low doses of radiation. This can be difficult for parents of young children.",
"    </p>",
"    <p>",
"     You will need to see your doctor or nurse on a regular basis after treatment to have your thyroid hormone levels checked and monitor for hypothyroidism or recurrent hyperthyroidism.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although surgical removal of the thyroid is a permanent cure for hyperthyroidism, it is used far less often than antithyroid drugs or radioactive iodine because of the risks (and expense) associated with thyroid surgery. The risks include damage to the nerves of the voice box and parathyroid glands, which regulate the body's calcium balance.",
"    </p>",
"    <p>",
"     However, surgery is recommended when:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A large goiter blocks the airways, making it difficult to breathe",
"      </li>",
"      <li>",
"       You cannot tolerate antithyroid drugs and you do not want to use radioiodine",
"      </li>",
"      <li>",
"       There is a nodule in the thyroid gland that could be cancer",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The follow-up after surgery includes regular appointments to test your thyroid hormone levels and monitor for signs of hypo- and hyperthyroidism. Most people develop hypothyroidism after surgery and require treatment with thyroid hormone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PREGNANCY AND HYPERTHYROIDISM",
"     </span>",
"    </p>",
"    <p>",
"     Women who take antithyroid drugs and want to become pregnant should discuss this with their doctor or nurse. There are risks to the mother and developing baby if hyperthyroidism is not well controlled; these risks can be avoided or minimized with frequent monitoring and medication adjustment throughout the pregnancy.",
"    </p>",
"    <p>",
"     Women who are pregnant or breastfeeding should not be treated with radioactive iodine. Having radioactive iodine treatment before becoming pregnant",
"     <strong>",
"      usually",
"     </strong>",
"     eliminates the need for antithyroid drugs and any possible associated risks. A woman should wait at least six months after radioactive iodine treatment before trying to become pregnant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287517713\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053333862\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=see_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=see_link\">",
"      Patient information: Congenital hypothyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=see_link\">",
"      Patient information: Multinodular goiter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=see_link\">",
"      Patient information: Periodic paralysis syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=see_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=see_link\">",
"      Patient information: Thyroiditis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053333889\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=see_link\">",
"      Patient information: Thyroid nodules (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Thyroid Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.thyroid.org/\">",
"      www.thyroid.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Thyroid Foundation of Canada",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thyroid.ca/\">",
"      www.thyroid.ca",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/thyroid.cfm\">",
"      www.hormone.org/public/thyroid.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Thyroid Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://thyroid.about.com/forum\">",
"      file://thyroid.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/6/3172/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/6/3172?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3172/abstract/1\">",
"      Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3172/abstract/2\">",
"      Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3172/abstract/3\">",
"      Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273:808.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_6_3172=[""].join("\n");
var outline_f3_6_3172=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HYPERTHYROIDISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS THE THYROID?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HYPERTHYROIDISM CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HYPERTHYROIDISM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HYPERTHYROIDISM DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           HYPERTHYROIDISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PREGNANCY AND HYPERTHYROIDISM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\" title=\"figure 1\">",
"           Thyroid anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/45/42704\" title=\"figure 2\">",
"           Overactive thyroid PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_6_3173="Bacitracin, neomycin, and polymyxin B: Patient drug information";
var content_f3_6_3173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, and polymyxin B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18660?source=see_link\">",
"     see \"Bacitracin, neomycin, and polymyxin B: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/37/33363?source=see_link\">",
"     see \"Bacitracin, neomycin, and polymyxin B: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neo-Polycin&trade;;",
"     </li>",
"     <li>",
"      Neosporin&reg; Neo To Go&reg; [OTC];",
"     </li>",
"     <li>",
"      Neosporin&reg; Topical [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bacitracin, neomycin, polymyxin B, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use longer than needed. A second infection may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when putting on. Staining may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid wearing contacts unless told to wear them by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The treated part may be covered with a dressing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull down lower eyelid of affected eye/eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin film of ointment into the lower eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close eye and roll eyeball around for 1 to 2 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use other eye drugs 10 minutes after the ointment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11132 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-B88327F15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3173=[""].join("\n");
var outline_f3_6_3173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138769\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022522\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022521\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022526\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022527\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022529\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022524\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022525\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022530\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022531\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18660?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/37/33363?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_6_3174="Treatment of early (stage I and II) head and neck cancer: The oropharynx";
var content_f3_6_3174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Carol R Bradford, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Avraham Eisbruch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Francis P Worden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3174/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/6/3174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal squamous cell carcinomas arise in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula, the fold located between the base of tongue and the epiglottis (",
"    <a class=\"graphic graphic_figure graphicRef65105 \" href=\"UTD.htm?1/5/1113\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of early squamous cell cancers of the oropharynx is reviewed here. The treatment of locally advanced cancers is discussed separately, as is the management of metastatic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375071\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal squamous cell carcinomas are relatively uncommon malignancies with approximately 123,000 cases of oropharyngeal and hypopharyngeal cancer diagnosed worldwide each year and about 79,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tobacco and alcohol use has been the principal risk factor for these cancers. Despite the decreasing prevalence of smoking, there is an increasing incidence of oropharyngeal cancers, particularly in younger adults. These trends are related to an increase in cancers caused by human papillomavirus (HPV) infection.",
"   </p>",
"   <p>",
"    These HPV associated cancers arise predominantly in the oropharynx in the tonsillar area and at the base of the tongue; HPV associated oropharyngeal cancers are associated with a better prognosis than other cancers in this region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify oropharyngeal carcinoma (",
"    <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By definition, patients with early (stage I and II) disease have tumors &lt;4 cm in greatest dimension without invasion into surrounding structures and have no evidence of lymph node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375187\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375735\">",
"    <span class=\"h2\">",
"     Surgery versus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early squamous cell carcinomas of the oropharynx can often be treated with either surgery or radiation therapy (RT) as a single modality. Definitive RT and primary surgery have yielded similar rates of local control and survival in retrospective studies, although there are no prospective randomized trials comparing the two approaches. The morbidity associated with each treatment approach is an important factor in making treatment decisions.",
"   </p>",
"   <p>",
"    RT is used more commonly, but surgery may be preferred in selected situations. Minimally invasive techniques such as transoral laser microsurgery (TLM) and transoral robotic surgery (TORS) have made resection of carefully selected early oropharyngeal cancers both feasible and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375742\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of RT to the primary tumor and regional lymph nodes and the optimal techniques for radiation administration are discussed separately, as are the complications associated with RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375749\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of occult neck metastases in a patient with oropharyngeal cancer and a clinically negative neck is relatively high. Thus, elective treatment of the neck is generally performed.",
"   </p>",
"   <p>",
"    Ipsilateral nodal treatment is generally sufficient to minimize the risk of neck recurrence in lateralized tonsil primaries; however, both sides of the neck require treatment for tumors arising in the midline (eg, base of tongue, soft palate, pharyngeal wall). For patients managed with primary RT, neck irradiation is generally used. For those who initially undergo resection of their primary tumor, a selective neck dissection is usually performed (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636375194\">",
"    <span class=\"h1\">",
"     SPECIFIC TUMOR SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Soft palate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early cancer of the soft palate are usually treated with RT to the primary tumor and the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/7\">",
"     7",
"    </a>",
"    ]. Locoregional control and survival with RT are comparable to outcomes with surgery. However, primary surgery is generally associated with greater functional impairment, particularly velopharyngeal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with stage I soft palate cancers, five-year locoregional control, cause-specific survival, and overall survival rates of 84, 89, and 52 percent, respectively, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Similar rates have been published for patients with stage II disease (85, 87, and 61 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tonsillar cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early tonsillar cancers can be treated with either primary surgery or RT, with similar outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. The majority of cases of tonsillar cancer are now HPV related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary RT is usually preferred because it results in good tumor control with a potentially better functional outcome than surgery. In one series, reported five-year local control and cause-specific survival rates following initial RT were 88 and 100 percent for stage I disease and 84 and 86 percent for stage II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small tumors confined to the tonsil (ie, surrounded by normal tissue) can be treated with simple tonsillectomy. If surgery is used for tumors that extend beyond the tonsil itself, the pharyngeal wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soft palate should be included in the resection.",
"   </p>",
"   <p>",
"    For these more extensive, but still early stage tumors, there are several surgical approaches, including an anterior approach (a combined lip splitting incision coupled with an anterior midline or lateral mandibulotomy) and a transhyoid approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Because these more extensive tumors often involve the base of tongue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soft palate, they may be best treated with nonsurgical approaches to limit patient morbidity. Transoral laser microsurgery and robotic surgery may avoid the morbidity associated with the anterior approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Base of tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinomas arising at the base of tongue are more aggressive than other oropharyngeal lesions. Since RT typically results in comparable outcomes but with a better functional outcome than primary surgery, RT is usually the preferred treatment for early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of occult lymph node metastasis is higher than for other oropharyngeal subsites, ranging from 21 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/17\">",
"     17",
"    </a>",
"    ]. Elective RT is recommended to the lymph node basins at risk for patients who are treated with primary RT, while lymph node dissection is recommended for patients who underwent surgical resection.",
"   </p>",
"   <p>",
"    Surgery for early unilateral base of tongue cancer consists of hemiglossectomy. These tumors have been traditionally removed by resecting the mandible or using a translabial transmandibular approach. However, these procedures involve significant morbidity including lip and chin scars, malocclusion, compromised swallowing, chronic aspiration, and altered speech articulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/18\">",
"     18",
"    </a>",
"    ]. Several investigators have reported success with transpharyngeal approaches, which allow wide exposure of the tongue base and superior tonsil and avoid the potential complications of mandibular osteotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transoral laser microsurgery uses an endoscope to view the pharynx through the mouth and a laser to excise the tumor. For appropriately selected patients with base of tongue cancers, transoral laser microsurgery may improve local control and functional results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. As an example, one study reported two-year local control and survival of 100 and 92 percent for T1 lesions and 87 and 91 percent for T2 lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared to conventional open surgery, transoral laser microsurgery minimizes the risk of fistula, flap failure, abscess, or osteoradionecrosis and is associated with a shorter hospital stay. However, postoperative hemorrhage occurs in 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Similar results have been obtained with transoral robotic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With either RT or surgery, primary tumors of the base of tongue are associated with lower disease-specific survival compared with other oropharyngeal cancers (65 and 54 percent, for stages I and II, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I and II oropharyngeal cancers are most commonly managed initially with either RT or surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with residual disease after primary RT are managed with salvage surgery.",
"     </li>",
"     <li>",
"      Patients initially treated with surgery should receive postoperative RT with or without concurrent chemotherapy for positive or close resection margins, extracapsular extension of lymph node disease, or other high risk features, such as lymphovascular and perineural invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3174/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=see_link\">",
"       \"Postoperative radiation therapy in the management of head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of early oropharyngeal cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur during this period. Continued follow-up beyond five years is generally suggested because of the risk of late recurrence and for second primary malignancies. Because of the increased risk of recurrence and second primary malignancy in those who continue tobacco use, more frequent surveillance visits and longer duration of follow-up is indicated for patients who continue tobacco use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal squamous cell carcinomas can arise in the soft palate, tonsils, base of tongue, pharyngeal wall, and vallecula.",
"     </li>",
"     <li>",
"      Early stage tumors can be effectively treated with single modality therapy, using either radiation therapy or surgery. (See",
"      <a class=\"local\" href=\"#H636375735\">",
"       'Surgery versus RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend routine elective neck treatment for all patients with early stage (N0 by definition) oropharyngeal cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). To minimize the risk of a neck recurrence, bilateral treatment is indicated for tumors on or near the midline; ipsilateral neck treatment is sufficient for other cases. (See",
"      <a class=\"local\" href=\"#H636375749\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no data to indicate that HPV associated cancers should be treated differently from other squamous cell carcinomas arising in the oropharynx, although several reports suggest that patients with HPV associated cancer have improved survival rates relative to patients with HPV negative cancers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/2\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/3\">",
"      Genden EM, Kotz T, Tong CC, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011; 121:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/4\">",
"      Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990; 12:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/5\">",
"      Lim YC, Koo BS, Lee JS, et al. Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck. Laryngoscope 2006; 116:1148.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/8\">",
"      Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys 2004; 59:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/9\">",
"      Chera BS, Amdur RJ, Hinerman RW, et al. Definitive radiation therapy for squamous cell carcinoma of the soft palate. Head Neck 2008; 30:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/10\">",
"      Erkal HS, Serin M, Amdur RJ, et al. Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys 2001; 50:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/11\">",
"      Charbonneau N, G&eacute;linas M, del Vecchio P, et al. Primary radiotherapy for tonsillar carcinoma: a good alternative to a surgical approach. J Otolaryngol 2006; 35:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/12\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol 2006; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/13\">",
"      Civantos F, Wenig BL. Transhyoid resection of tongue base and tonsil tumors. Otolaryngol Head Neck Surg 1994; 111:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/14\">",
"      Agrawal A, Wenig BL. Resection of cancer of the tongue base and tonsil via the transhyoid approach. Laryngoscope 2000; 110:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/15\">",
"      Moore EJ, Olsen KD, Kasperbauer JL. Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope 2009; 119:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/16\">",
"      Weinstein GS, O'Malley BW Jr, Snyder W, et al. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/17\">",
"      Pillsbury HC 3rd, Clark M. A rationale for therapy of the N0 neck. Laryngoscope 1997; 107:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/18\">",
"      Gourin CG, Johnson JT. Surgical treatment of squamous cell carcinoma of the base of tongue. Head Neck 2001; 23:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/19\">",
"      Zeitels SM, Vaughan CW. Tongue-base-cancer resection with partial supraglottic laryngectomy. Am J Otolaryngol 1994; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/20\">",
"      Nasri S, Oh Y, Calcaterra TC. Transpharyngeal approach to base of tongue tumors: a comparative study. Laryngoscope 1996; 106:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/21\">",
"      Steiner W, Fierek O, Ambrosch P, et al. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2003; 129:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/22\">",
"      Grant DG, Salassa JR, Hinni ML, et al. Carcinoma of the tongue base treated by transoral laser microsurgery, part one: Untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006; 116:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/23\">",
"      Sessions DG, Lenox J, Spector GJ, et al. Analysis of treatment results for base of tongue cancer. Laryngoscope 2003; 113:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3174/abstract/24\">",
"      Zhen W, Karnell LH, Hoffman HT, et al. The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 2004; 26:660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3399 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3174=[""].join("\n");
var outline_f3_6_3174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636375071\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636375187\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636375735\">",
"      Surgery versus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636375742\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636375749\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636375194\">",
"      SPECIFIC TUMOR SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Soft palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tonsillar cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Base of tongue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3399|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/5/1113\" title=\"figure 1\">",
"      Subdivisions pharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/55/36733\" title=\"table 1\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_6_3175="Acute ISN and minimal change";
var content_f3_6_3175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Light micrograph of kidney biopsy of a patient with acute interstitial nephritis, acute kidney injury, and nephrotic syndrome after treatment with a cephalosporin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 205px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal biopsy from a patient who developed acute renal failure and the nephrotic syndrome following therapy with a cephalosporin.",
"    <br/>",
"    (Left panel) Evidence of interstitial nephritis characterized by an interstitial infiltrate and separation of the tubules due to interstitial edema.",
"    <br/>",
"    (Middle panel) Light microscopy shows a normal glomerulus.",
"    <br/>",
"    (Right panel) Electron microscopy reveals diffuse foot process fusion consistent with minimal change disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3175=[""].join("\n");
var outline_f3_6_3175=null;
var title_f3_6_3176="Child injury statement B";
var content_f3_6_3176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Child injury statement, page 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 634px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hospitals and or states may have specific forms for reporting child abuse and or neglect. The form used by Texas Children's Hospital is shown as an example. When child abuse is reported by a physician, a copy of the written report should be filed in the patient's medical record.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3176=[""].join("\n");
var outline_f3_6_3176=null;
var title_f3_6_3177="Overview of thoracic outlet syndromes";
var content_f3_6_3177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of thoracic outlet syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Kaoru Goshima, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Matthew L White, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3177/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/6/3177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H455545309\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic outlet syndrome (TOS) refers to a constellation of signs and symptoms that arise from compression of the neurovascular bundle by various structures in the area just above the first rib and behind the clavicle, within the confined space of the thoracic outlet [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ]. Historically, several names have been coined to describe pathology involving the thoracic outlet, including cervical rib syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/2\">",
"     2",
"    </a>",
"    ], scalene anticus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/3\">",
"     3",
"    </a>",
"    ], costoclavicular syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/4\">",
"     4",
"    </a>",
"    ], and hyperabduction syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/5\">",
"     5",
"    </a>",
"    ]. The term &ldquo;thoracic outlet syndrome&rdquo; was coined to collectively encompass the spectrum of syndromes related to the general region of the thoracic outlet [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distinct terms are used to describe the predominantly affected structure, including neurogenic (nTOS) from brachial plexus compression, venous (vTOS) from subclavian vein compression, and arterial (aTOS) from subclavian artery compression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/7\">",
"     7",
"    </a>",
"    ]. Neurogenic TOS is subdivided into true and disputed forms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/8\">",
"     8",
"    </a>",
"    ]. Disputed neurogenic TOS accounts for greater than 95 percent of cases of thoracic outlet syndrome, whereas vTOS accounts for 3 percent and aTOS accounts for 1 percent of cases. True neurogenic TOS is rare. [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1,9-13\">",
"     1,9-13",
"    </a>",
"    ]. Compression of the brachial plexus leads to upper extremity numbness, dysesthesia and weakness; venous compression may cause deep vein thrombosis and extremity swelling; and arterial compression can lead to distal thromboembolism, arm pain with exertion (&lsquo;claudication&rsquo;) or acute arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    An overview of the anatomy, pathogenesis, clinical evaluation and approach to the management of the thoracic outlet syndromes will be reviewed with an emphasis on the features that distinguish these syndromes from one another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455545323\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic outlet is bounded by the bony structures of the spinal column, first ribs, and sternum (",
"    <a class=\"graphic graphic_figure graphicRef59433 \" href=\"UTD.htm?17/58/18338\">",
"     figure 1",
"    </a>",
"    ). Compromise of the neurovascular structures that traverse the thoracic outlet occurs in three distinct spaces: the scalene triangle, the costoclavicular space, and the pectoralis minor space.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scalene triangle &ndash; The scalene triangle is the space most commonly involved in TOS and is the most common site of brachial plexus compression. The anterior scalene muscle, which originates from the transverse processes of the third through sixth cervical vertebrae (C3-C6) and inserts on the inner borders and superior surfaces of the first rib, forms the anterior boundary of the scalene triangle. The middle scalene muscle, which arises from the transverse processes of the second through seventh cervical vertebrae (C2-C7) and inserts broadly onto the posterior aspects of the first rib, forms the posterior wall of the scalene triangle. The superior border of the first rib forms the base of the scalene triangle. The trunks of the brachial plexus and the subclavian artery pass between the anterior and middle scalene muscles while the subclavian vein courses anteromedial to the scalene triangle. Cervical ribs and anomalous first ribs may compress the scalene triangle (",
"      <a class=\"graphic graphic_figure graphicRef50430 \" href=\"UTD.htm?38/46/39650\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Costoclavicular space &ndash; The costoclavicular space comprises the area between the first rib and the clavicle. The brachial plexus, subclavian artery and subclavian vein pass through this space. Of these, the subclavian vein is most likely to be compressed at this site.",
"     </li>",
"     <li>",
"      Pectoralis minor space &ndash; The pectoralis minor space is bounded by the pectoralis minor muscle anteriorly and the chest wall posteriorly. Although this space is not technically a part of the thoracic outlet, the brachial plexus, subclavian artery and subclavian vein pass through the pectoralis minor space to the upper arm. Compression of the neurovascular structures within the pectoralis minor space may be nearly as common as compression within the scalene triangle [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455545331\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the neurovascular bundle as it traverses the thoracic outlet can result from a combination of developmental abnormalities, injuries and physical activities that predispose to neurovascular compression. Variants in thoracic outlet anatomy, both congenital and acquired, are common and include primarily variations in bony and muscular anatomy. A study that examined 200 consecutive patients undergoing thoracic outlet surgery found that 8.5 percent of patients had a cervical rib articulating with the first thoracic rib, 10 percent had supernumerary scalene muscles, and 43 percent had variations in scalene muscle attachments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/16\">",
"     16",
"    </a>",
"    ]. Alterations in brachial plexus anatomy and muscle histology may also contribute.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anomalous ribs &ndash; Cervical ribs were first described in the 18",
"      <sup>",
"       th",
"      </sup>",
"      century and subsequently classified in the 19",
"      <sup>",
"       th",
"      </sup>",
"      century into four types based upon length and union with the first rib [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/17\">",
"       17",
"      </a>",
"      ]. These rib abnormalities have long been associated with symptoms of neurovascular compression [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. A higher incidence of bony abnormalities, such as a cervical rib or anomalous first rib, is found in patients with TOS. Cervical ribs occur in approximately 1 percent of the population and are bilateral in 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. About 70 percent of patients with cervical ribs are women [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"       1",
"      </a>",
"      ]. The presence of a cervical rib predisposes the patient to develop TOS after hyperextension-flexion (whiplash) injury [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Congenital cervical fibro-cartilaginous bands associated with",
"      <sup>",
"      </sup>",
"      an incomplete cervical rib have also been associated with TOS. The pathologic problem in true neurogenic TOS is not the cervical rib itself but a radiolucent band that extends from the tip of the rudimentary cervical rib to the first thoracic rib and compresses the proximal lower trunk of the brachial plexus [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscular anomalies &ndash; Pre-existing variations in muscle anatomy can narrow the space between the anterior and middle scalene muscles. The insertions of these muscles are variable, and overlap of these muscle insertions can narrow the space through which the brachial plexus and subclavian artery pass. Supernumerary scalene muscles can be present. Occasionally, there is complete fusion of the anterior and middle scalene muscles. Cervical fibro-cartilaginous bands may predispose a patient to TOS. Subclavius muscle variations have also been associated with TOS. Acquired variations in muscle anatomy include hypertrophy of the scalene, subclavius, or pectoralis minor muscles, as might be seen in weight lifters. Histologic variations in muscle fiber anatomy may also contribute to TOS. One study demonstrated a type 1 fiber predominance and fiber hypertrophy in the anterior scalene muscles of TOS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/24\">",
"       24",
"      </a>",
"      ]. In another study, increased scalene connective tissue content with fibrosis surrounding individual muscle fibers was found in TOS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injury &ndash; Chronic inflammatory change due to trauma is the most common etiology of acquired variant anatomy in TOS. The most common injury associated with disputed neurogenic TOS is",
"      <span class=\"nowrap\">",
"       hyperextension/flexion",
"      </span>",
"      injury of the neck, such as might occur in a motor vehicle accident. Other etiologies of injury include bony fracture (first rib, clavicle) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/26\">",
"       26",
"      </a>",
"      ], a fall from standing, (such as onto an icy surface), repetitive neck movement, repetitive occupational overhead arm movements (eg, box stacking), or repetitive athletic arm movements (eg, pitching, swimming). Repetitive injury can lead to any of the three types of TOS (neurogenic, arterial, venous) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Patients with first-rib or clavicular fractures can develop callous formation or pseudoarthrosis that can lead to neurovascular compression. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293627701\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations, diagnosis, and approach to management of each type of TOS including true neurogenic (nTOS), disputed nTOS, venous (vTOS) and arterial (aTOS) are unique, reflecting compression of a specific structure, although there may be some overlap in symptoms if more than one structure is affected. A thorough physical examination that includes a complete neurologic and vascular evaluation should be performed on all patients.",
"   </p>",
"   <p>",
"    Compression maneuvers on physical examination (ie, Adson test) may demonstrate a decrease in the radial or ulnar pulse with abduction of the upper extremity overhead. The Adson test is prone to false positive results and the use of duplex ultrasound with these maneuvers has done little to improve its specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the Adson test is of little clinical value and should not be relied upon to make the diagnosis of any of the three types of TOS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455545366\">",
"    <span class=\"h2\">",
"     True neurogenic TOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;True neurogenic TOS (also called classic TOS) is rare, with an estimated incidence of 1:1,000,000. Symptoms of true neurogenic TOS include slowly progressive unilateral atrophic weakness of the intrinsic hand muscles that is more evident on the thenar aspect of the hand rather than the hypothenar aspect. Sensory abnormalities in the T1 distribution (",
"    <a class=\"graphic graphic_figure graphicRef53938 \" href=\"UTD.htm?22/19/22836\">",
"     figure 3",
"    </a>",
"    ) are common. The syndrome may be caused by a taut congenital band from the first rib to the tip of an elongated C7 transverse process. The lower portion of the plexus is stretched over this band, and chronic traction injury results. This explains why true TOS has the clinical features of a lower trunk plexopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488964654\">",
"    <span class=\"h2\">",
"     Disputed neurogenic TOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disputed neurogenic TOS (also called nonspecific or symptomatic TOS) is the most controversial form, and accounts for approximately 95 percent of all cases of TOS, and 99 percent of cases with neurologic symptoms. [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Proponents of this entity believe that pathologic processes in the thoracic outlet, such as soft tissue anomalies that can only be appreciated at time of surgery, are the cause of a myriad of symptoms affecting the neck, shoulder, and arm, including involvement of upper trunk nerves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In disputed TOS, tenderness over the scalene muscles is usually present, and muscle atrophy",
"    <span class=\"nowrap\">",
"     (arm/hand)",
"    </span>",
"    is a rare finding. Symptoms are reproducibly exacerbated by any activity that requires elevation or sustained use of the arms or hands. These activities include reaching overhead (eg, brushing the hair, getting objects from a cabinet), overhead lifting, prolonged typing or work at a computer, driving, and speaking on the telephone. Provocative maneuvers including neck rotation and head tilting, arm abduction and external rotation and the upper limb tension test may duplicate the patient&rsquo;s symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\", section on 'Provocative maneuvers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455545401\">",
"    <span class=\"h2\">",
"     Venous TOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of venous compression are the second most common clinical finding of TOS, accounting for about 3 percent of cases. Venous TOS typically occurs in individuals who perform vigorous repetitive exertion of the upper extremities, usually with the arms above shoulder level [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ]. Forearm fatigue within minutes of using the arm may be present in vTOS.",
"   </p>",
"   <p>",
"    Swelling can be accompanied by pain and cyanosis of the affected extremity; paresthesias in the fingers are common but are a manifestation of swelling in the hand rather than nerve compression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ]. Collateral venous patterning may be seen in the skin overlying the ipsilateral shoulder, neck, and chest wall and indicates compensatory superficial venous flow due to subclavian vein stenosis or occlusion.",
"   </p>",
"   <p>",
"    Upper extremity edema due to varying degrees of venous compression or overt deep vein thrombosis is the hallmark of vTOS. Upper extremity venous thrombosis due to thoracic outlet compression is termed &ldquo;spontaneous&rdquo; to distinguish it from instrumentation-related or &ldquo;catheter-induced&rdquo; venous thrombosis. Spontaneous upper extremity venous thrombosis is historically referred to as Paget-Schroetter syndrome or &ldquo;effort&rdquo; thrombosis. Spontaneous upper extremity venous thrombosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455545436\">",
"    <span class=\"h2\">",
"     Arterial TOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of arterial compression comprise the least common type of thoracic outlet syndrome, accounting for only about 1 percent of cases. Symptoms develop spontaneously unrelated to work or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ]. Arterial TOS is almost always associated with a cervical rib or anomalous rib. It occurs in young patients without typical atherosclerotic risk factors distinguishing it from peripheral artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=see_link\">",
"     \"Overview of upper extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hand ischemia with symptoms of pain, pallor, paresthesia, and coldness is the most common presentation. These symptoms are due to arterial thromboembolization arising from mural thrombus from the subclavian artery or a subclavian aneurysm. In young women, this etiology must be differentiated from the Raynaud phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other presentations include upper extremity pain with activity due to subclavian artery stenosis or occlusion. Rarely, thrombus from the subclavian artery can propagate and embolize retrograde, causing stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/30\">",
"     30",
"    </a>",
"    ]. However, because of the rich collateral circulation around the shoulder (",
"    <a class=\"graphic graphic_figure graphicRef66933 \" href=\"UTD.htm?18/1/18454\">",
"     figure 4",
"    </a>",
"    ), arm ischemia is uncommon.",
"   </p>",
"   <p>",
"    On physical examination, patients may have a lower systolic blood pressure in the affected arm and distal pulses at the wrist may be diminished or absent. In patients with thromboembolism, finger ischemia or patchy ischemic skin may be present. A bruit or a thrill may be appreciated over the subclavian artery, and in patients who have developed post-stenotic aneurysmal changes, a pulsatile supraclavicular mass may be palpable. In contrast to patients with disputed nTOS, the scalene muscles will not be tender and provocative maneuvers will not elicit any symptoms. (See",
"    <a class=\"local\" href=\"#H455545366\">",
"     'True neurogenic TOS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293628070\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical symptoms and signs direct the nature of further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293628493\">",
"    <span class=\"h2\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiological evaluation is indicated in anyone with suspected neurogenic TOS.",
"   </p>",
"   <p>",
"    The electrophysiological signature of neurogenic TOS is quite specific, though not sensitive. The ulnar sensory potential amplitude is reduced or absent, in contrast with a normal median sensory potential. However, the ulnar motor potential is reduced out of proportion to the median. Abnormalities in the medial antebrachial cutaneous nerve (which approximates the T1 root distribution) are almost always present. Electromyography usually confirms the greater involvement of thenar versus hypothenar hand muscles. The electrodiagnostic testing criteria for true nTOS are discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of disputed nTOS is purely clinical, as there are no positive objective electrodiagnostic or laboratory findings. Brachial plexus (interscalene) block (local anesthetic injected into the anterior scalene muscle) may be a helpful diagnostic maneuver for disputed nTOS; a positive response (relief of symptoms) helps predict success with surgical decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H13#H13\">",
"     \"Peripheral nerve block: Techniques\", section on 'Interscalene block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293629306\">",
"    <span class=\"h2\">",
"     Physiologic vascular studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity vascular studies may be useful in patients with suspected aTOS. In the setting of embolization, segmental pressures or pulse volume recordings can be used to localize the site of obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58549369#H58549369\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Physiologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293627869\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies can help confirm a suspected diagnosis of thoracic outlet syndrome. Chest x-rays are important to identify bony abnormalities such as cervical ribs, long transverse cervical processes, or",
"    <span class=\"nowrap\">",
"     rib/clavicular",
"    </span>",
"    fracture calluses. Because more than 90 percent of aTOS patients will have a bony abnormality, the absence of rib abnormalities nearly eliminates a diagnosis of aTOS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain cervical spine films in true neurogenic TOS often demonstrate an elongated C7 transverse process or a rudimentary cervical rib ipsilateral to the affected limb, and contralateral cervical rib is frequently present as well [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the pathologic problem in true nTOS is not the cervical rib itself but a radiolucent band that extends from the tip of the rudimentary cervical rib to the first thoracic rib and compresses the proximal lower trunk axons of the brachial plexus. This band is not visualized by plain films or computed tomography (CT) and is only occasionally detected by magnetic resonance imaging (MRI). Thus, CT and MRI are of little value for the diagnosis of true nTOS.",
"   </p>",
"   <p>",
"    Because diagnostic tests are often negative or equivocal in disputed nTOS, further imaging is primarily to exclude other conditions, such as degenerative cervical disk or spinal column disease, shoulder disease, and various forms of intracranial disease.",
"   </p>",
"   <p>",
"    For arterial and venous TOS, the diagnosis is supported by the demonstration of stenosis or occlusion of the corresponding subclavian vessel in a patient with an appropriate clinical history.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasound &ndash; Ultrasonography is the initial imaging test to evaluate aTOS or vTOS because it is inexpensive and noninvasive. Duplex ultrasound is a highly sensitive and specific test for venous stenosis or occlusion when performed by an experienced vascular ultrasound technician [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. For aTOS, duplex ultrasonography may demonstrate an increased flow velocity in the subclavian artery at the site of a stenosis or aneurysmal degeneration of the artery distal to a stenosis. These findings in a patient with a typical clinical history and no risk factors for atherosclerosis support a diagnosis of aTOS. Equivocal duplex studies are followed up with additional imaging.",
"     </li>",
"     <li>",
"      Computed tomography &ndash; For further anatomic detail, computed tomography (CT) demonstrates the relationship of vascular structures to surrounding bone and muscle. CT angiography and venography produce high-quality images of the central vasculature and extremity vessels and three-dimensional reconstruction is increasingly being used to identify the point of vascular compression and assess the extent of pathology.",
"     </li>",
"     <li>",
"      Magnetic resonance &ndash; Magnetic resonance (MR) angiography is generally not indicated for the diagnosis of TOS. For vTOS, MR venography can be performed if a patient has a fixed lesion limited to a central vein. However, under this circumstance, we prefer to obtain a contrast venogram.",
"     </li>",
"     <li>",
"      Conventional",
"      <span class=\"nowrap\">",
"       arteriography/venography",
"      </span>",
"      &ndash; In many centers, conventional arteriography has been supplanted by CT angiography for the diagnosis of aTOS; however, arteriography may still be needed for patients who have signs and symptoms of acute arterial insufficiency or ischemia, and to plan surgical reconstruction. The advantage of arteriography and venography is the ability to obtain dynamic studies in which the patient performs upper extremity maneuvers during imaging to assist in identifying arterial or venous compression, or to initiate thrombolytic therapy, if indicated. Although contrast venography is not always needed to establish a diagnosis of vTOS, early intervention with catheter-based thrombolytic therapy appears to be associated with improved outcomes. When noninvasive testing is normal and there is a high degree on suspicion for vTOS we obtain a venogram. (See",
"      <a class=\"local\" href=\"#H293628810\">",
"       'Anticoagulation/thrombolysis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293628520\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment approach depends upon the type of TOS. Treatment is indicated only for symptomatic patients. The mere presence of a cervical rib or other rib anomalies does",
"    <strong>",
"     not",
"    </strong>",
"    indicate a need to intervene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"     1",
"    </a>",
"    ]. Autopsy series demonstrate that about 0.5 percent of the population have cervical ribs and only a fraction of these patients ever develop symptoms of TOS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293628803\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disputed neurogenic TOS should initially be managed with physical therapy for a period of at least four to six weeks. Patients need to be referred to physical therapists with specific expertise in treating disputed nTOS, given that this entity is distinct from other disorders that affect the neck, shoulder, and arm. Exercises strengthen the muscles surrounding the shoulder and postural exercises help the patient to sit and stand straighter, potentially lessening pressure on neurovascular structures in the thoracic outlet. Other conservative measures include passage of time and weight reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293628810\">",
"    <span class=\"h2\">",
"     Anticoagulation/thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of vTOS historically involved only systemic anticoagulation combined with extremity rest and elevation; however, this approach resulted in long-term morbidity in up to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Treatment of subclavian thrombosis with catheter-directed thrombolysis is the preferred initial treatment for vTOS. Success rates for re-establishing subclavian vein patency are nearly 100 percent provided thrombolysis is performed within two weeks of the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link&amp;anchor=H239066343#H239066343\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Approach to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following restoration of venous patency, persistent venous stenosis and evidence of residual external compression are typical. Some clinicians favor anticoagulation for one to three months following successful thrombolysis to allow endothelial healing and resolution of acute inflammation before definitive thoracic outlet decompression surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/42\">",
"     42",
"    </a>",
"    ]. However, given the significant risk of reocclusion, most advocate surgical decompression during the same hospitalization as thrombolytic therapy. Decompression as early as four hours after thrombolysis appears to be safe and reduces reocclusion of the subclavian vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H293625095\">",
"     'Thoracic outlet decompression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293631715\">",
"    <span class=\"h2\">",
"     Managing ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild degrees of acute arterial ischemia due to distal embolization from aTOS, catheter-directed thrombolysis may be appropriate before surgical repair. However, more severe ischemia usually requires surgical embolectomy (with or without intraoperative thrombolysis) in conjunction with thoracic outlet decompression. A conduit is usually required, but occasionally, the subclavian artery has a short injury amenable to resection and primary anastomosis. Acceptable conduits include the great saphenous vein, femoral vein, ringed polytetrafluoroethylene, and polyester (ie, Dacron&reg;). Distal bypass may be necessary for patients with distal vascular occlusions due to chronic embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link\">",
"     \"Subclavian steal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute ischemia of the upper extremity of sufficient duration may lead to a compartment syndrome; upper extremity fasciotomy may be required. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293625095\">",
"    <span class=\"h1\">",
"     THORACIC OUTLET DECOMPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first operations for thoracic outlet compression described treatment of subclavian artery aneurysms in patients with cervical ribs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/44\">",
"     44",
"    </a>",
"    ]. Anterior scalenotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/45\">",
"     45",
"    </a>",
"    ] and, later, other operative approaches to rib resection in TOS were described, including a posterior thoracotomy approach (no longer used), transaxillary approach, supraclavicular approach and infraclavicular approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293631442\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic outlet decompression is indicated for",
"    <strong>",
"     symptomatic",
"    </strong>",
"    patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular TOS (aTOS, vTOS) in patients who are not at high risk for surgery.",
"     </li>",
"     <li>",
"      Selected patients with true nTOS who have acute or subacute progressive neurologic weakness or disabling pain and paresthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/49\">",
"       49",
"      </a>",
"      ]. Surgical release of the fibrous band or resection of the rudimentary cervical rib is appropriate before weakness becomes chronic and severe. Following surgical decompression, symptoms of pain may respond, but strength is unlikely to return do to axonal damage [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery for disputed nTOS can be considered, but only for patients who have failed conservative physical therapy. Surgical decompression in this population should not to be undertaken lightly because of the potential for postoperative complications that can include postoperative iatrogenic brachial plexopathy, and high recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293627619\">",
"    <span class=\"h2\">",
"     Approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three surgical approaches are used for thoracic outlet decompression: the transaxillary, supraclavicular, and infraclavicular approaches. The choice of procedure depends upon the anatomic abnormalities that are identified and surgeon preference.",
"   </p>",
"   <p>",
"    The transaxillary approach to thoracic outlet decompression has the advantage of more complete visualization of the rib during resection, but it does not allow for vascular reconstruction. The approach requires a limited amount of dissection and external scarring is minimized. A transverse incision is made at the inferior margin of the axilla from the pectoralis major anteriorly to the latissimus dorsi posteriorly. The incision is deepened to identify the lateral chest wall and continued superiorly to the thoracic outlet with care to avoid injury to the long thoracic and intercostal brachial nerve. The first rib is seen following identification of the axillary vessels and first thoracic nerve root. The subclavius and anterior scalene muscles are divided to free the first rib. Once the periosteum is cleared from the first rib, the rib is resected, which usually requires removing the rib in multiple pieces due to the confined space. The edges of the bone are smoothed with a file or rongeur.",
"   </p>",
"   <p>",
"    The supraclavicular approach to thoracic outlet decompression provides a wider exposure of the ribs and the site of compression can be directly identified; arterial reconstruction can be performed, as needed. The anterior and middle scalene muscles can be completely resected with this approach and brachial plexus neurolysis can also be performed. Resection of the first rib may not be needed to achieve sufficient decompression. Occasionally, an infraclavicular incision is needed to fully see the venous structures.",
"   </p>",
"   <p>",
"    The infraclavicular approach is particularly useful in cases of vTOS that require extensive venous reconstruction. Exposure of the central veins can be achieved by extending the incision medially and performing a transverse sternotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293627199\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of surgical decompression for thoracic outlet syndrome varies depending upon the clinical type.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disputed nTOS &ndash; Surgical success following decompressive surgery for disputed nTOS is somewhat subjective and based upon an individual&rsquo;s perception of disability before and after decompression. Currently, there is no common classification scheme for patient stratification. A comprehensive analysis of surgical outcomes for disputed nTOS found that the surgical approach does not seem to be important, and initial success rates are 91 to 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. With time, success appears to wane. At 10 years, the success rate among all approaches ranges from 64 percent to 71 percent. Factors that predict surgical failure include major depression, chronic symptoms, work-related injury, lack of response to anterior scalene muscle blocks, and diffuse arm symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/23,57-59\">",
"       23,57-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      True nTOS &ndash; With true neurogenic TOS, surgical release of the fibrous band or resection of the rudimentary cervical rib generally relieves symptoms of pain, but improvement in strength may require time to allow demyelinated axons to recover [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/50\">",
"       50",
"      </a>",
"      ]. Provided progressive axonal loss is arrested, some recovery can be expected, though in some cases recovery may not be complete.",
"     </li>",
"     <li>",
"      aTOS &ndash; For aTOS, long-term outcomes following thoracic outlet decompression correlate with the status of the distal circulation. Upper extremities with ischemia due to embolization have a worse prognosis. One report of 55 cases of aTOS found at a mean follow-up of 5.7 months, 91 percent of patients were asymptomatic, and 9 percent had exertional symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/14\">",
"       14",
"      </a>",
"      ]. Three of the four patients who were symptomatic at follow-up had required embolectomy for brachial artery occlusion which was associated with hand ischemia.",
"     </li>",
"     <li>",
"      vTOS &ndash; Long-term outcomes of treatment in properly selected patients are encouraging. Most patients undergoing successful thrombolysis followed by decompression have five-year secondary vein patency rates greater than 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3177/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"       \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293627611\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic outlet syndrome (TOS) refers to a constellation of signs and symptoms arising from compression of the upper extremity neurovascular bundle by various structures in the area just above the first rib and behind the clavicle, typically within the confined space of the thoracic outlet. The term thoracic outlet syndrome is not a specific diagnosis and the appropriate type of TOS, such as true neurogenic (nTOS), disputed nTOS, arterial (aTOS), or venous (vTOS) thoracic outlet syndrome should be used. (See",
"      <a class=\"local\" href=\"#H455545309\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thoracic outlet syndromes are due to rib anomalies, muscular anomalies, or a result of injury. Cervical ribs predispose the patient to TOS after hyperextension-flexion (whiplash) injury. The absence of a rib anomaly makes the diagnosis of arterial thoracic outlet syndrome less likely. Many patients with disputed nTOS have a prior history of neck trauma or repetitive occupational physical stress. Similarly, vTOS is highly associated with repetitive movements, particularly with repetitive overhead upper extremity movements. (See",
"      <a class=\"local\" href=\"#H455545331\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each type of thoracic outlet syndrome can usually be differentiated with clinical history, physical exam, neurophysiological testing, and imaging. Symptoms of true neurogenic TOS include slowly progressive unilateral atrophic weakness of the hypothenar hand muscles and numbness in the distribution of the ulnar nerve and medial antebrachial cutaneous nerves. Symptoms of disputed neurogenic TOS include upper extremity pain, dysesthesia, weakness, and numbness in the hand, arm, or shoulder. Tenderness over the scalene muscles is often present. Arterial TOS typically presents as thromboembolism to the hand or arm. Features of",
"      <span class=\"nowrap\">",
"       arm/hand",
"      </span>",
"      ischemia include pain, paresthesia, pallor and coolness. Venous TOS is easily differentiated from the other forms of TOS because venous compression may lead to upper extremity venous thrombosis, swelling, and cyanosis even in the absence of thrombosis. Due to swelling, some patients may complain of hand paresthesias, but this is rarely confused with true nTOS or disputed nTOS. (See",
"      <a class=\"local\" href=\"#H293627701\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrodiagnostic testing is required to establish the diagnosis of true nTOS, which is based upon a characteristic pattern of abnormalities on nerve conduction studies and electromyography. In contrast, the diagnosis of disputed nTOS is purely clinical, as there are no reliable objective laboratory findings. Arterial or venous duplex ultrasound are the initial diagnostic tests for aTOS or vTOS, respectively. There may be a limited role for computed tomographic or magnetic resonance imaging when duplex is equivocal. Conventional arteriography (aTOS) and venography (vTOS) remain useful diagnostic modalities in allowing dynamic testing (exam performed with various arm movements) and initiation of thrombolysis, if indicated. (See",
"      <a class=\"local\" href=\"#H293628070\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical release of the fibrous band or resection of the rudimentary cervical rib should be performed before weakness becomes chronic and severe in patients with true nTOS who have acute or subacute progressive neurologic weakness or disabling pain and paresthesia. Patients with disputed nTOS should be managed conservatively with physical therapy and weight loss. Patients who have not responded to these measures may become candidates for thoracic outlet decompression; however, the patient needs to understand that the long-term success rates for thoracic outlet decompression for disputed nTOS diminish over time. (See",
"      <a class=\"local\" href=\"#H293628803\">",
"       'Physical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H293627199\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with deep vein thrombosis due to vTOS, catheter-directed thrombolysis and early thoracic outlet decompression is performed to relieve extrinsic vein compression. Without decompression, recurrent thrombosis is common. In properly selected patients, long-term outcomes are excellent following thrombolysis and thoracic outlet decompression. (See",
"      <a class=\"local\" href=\"#H293628810\">",
"       'Anticoagulation/thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H293627199\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"       \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link&amp;anchor=H239066343#H239066343\">",
"       \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Approach to treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with aTOS are treated according to the nature of their symptoms and initial presentation. Patients with signs and symptoms of upper extremity thromboembolism undergo thoracic outlet decompression in conjunction with embolectomy, thrombolytic therapy, or anticoagulation. Arterial TOS is nearly always associated with a correctable anatomic bony abnormality, and, without decompression, the rate of recurrent thromboembolism is high. We prefer a supraclavicular approach for decompression combined with thrombectomy or thrombolysis (catheter directed prior to surgery or in conjunction with surgery) to manage arterial thrombosis. Occasionally, arterial reconstruction (ie, surgical bypass) may be needed. (See",
"      <a class=\"local\" href=\"#H293628810\">",
"       'Anticoagulation/thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H293631715\">",
"       'Managing ischemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H293627199\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/1\">",
"      Sanders RJ, Hammond SL, Rao NM. Diagnosis of thoracic outlet syndrome. J Vasc Surg 2007; 46:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/2\">",
"      Murphy, JB. Cervical rib excision: collective review on surgery of cervical rib. Clin John B Murphy 1916; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/3\">",
"      Ochsner, A, Gage, et al. Scalenus anticus (Naffziger) syndrome. Am J Surg 1935; 28:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/4\">",
"      Falconer, MA, Weddell, G. Costoclavicular compression of the subclavian artery and vein. Lancet 1943; 2:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/5\">",
"      Wright, IS. The neurovascular syndrome produced by hyperabduction of the arms. The immediate changes produced in 150 normal controls, and the effects on same persons of prolonged hyperabduction of the arms, as in sleeping, and in certain occupations. Am Heart J 1945; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/6\">",
"      PEET RM, HENRIKSEN JD, ANDERSON TP, MARTIN GM. Thoracic-outlet syndrome: evaluation of a therapeutic exercise program. Proc Staff Meet Mayo Clin 1956; 31:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/7\">",
"      Landry GJ, Moneta GL, Taylor LM Jr, et al. Long-term functional outcome of neurogenic thoracic outlet syndrome in surgically and conservatively treated patients. J Vasc Surg 2001; 33:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/8\">",
"      Wilbourn AJ. Thoracic outlet syndromes. Neurol Clin 1999; 17:477.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders, RJ. Thoracic Outlet Syndrome: General Considerations. In: Rutherford's Vascular Surgery, 7th ed, Cronenwett, JL, Johnston, KW (Eds), Saunders Elsevier, 2010. p.1865.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/10\">",
"      Atasoy E. Thoracic outlet compression syndrome. Orthop Clin North Am 1996; 27:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/11\">",
"      Christo PJ, McGreevy K. Updated perspectives on neurogenic thoracic outlet syndrome. Curr Pain Headache Rep 2011; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/12\">",
"      Gilliatt RW, Le Quesne PM, Logue V, Sumner AJ. Wasting of the hand associated with a cervical rib or band. J Neurol Neurosurg Psychiatry 1970; 33:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/13\">",
"      Wilbourn AJ. The thoracic outlet syndrome is overdiagnosed. Arch Neurol 1990; 47:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/14\">",
"      Cormier JM, Amrane M, Ward A, et al. Arterial complications of the thoracic outlet syndrome: fifty-five operative cases. J Vasc Surg 1989; 9:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/15\">",
"      Hood DB, Kuehne J, Yellin AE, Weaver FA. Vascular complications of thoracic outlet syndrome. Am Surg 1997; 63:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/16\">",
"      Makhoul RG, Machleder HI. Developmental anomalies at the thoracic outlet: an analysis of 200 consecutive cases. J Vasc Surg 1992; 16:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/17\">",
"      Halsted WS. AN EXPERIMENTAL STUDY OF CIRCUMSCRIBED DILATION OF AN ARTERY IMMEDIATELY DISTAL TO A PARTIALLY OCCLUDING BAND, AND ITS BEARING ON THE DILATION OF THE SUBCLAVIAN ARTERY OBSERVED IN CERTAIN CASES OF CERVICAL RIB. J Exp Med 1916; 24:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/18\">",
"      Hunauld. Sur le nombre des cotes, moindre ou plus grand qu'a l'ordinaire. Memoires de I'Academie Royale des Sciences 1740:377.",
"     </a>",
"    </li>",
"    <li>",
"     Gruber W. Ueber die Halsrippen des Menschen mit Vergleichend-anatomischen, Bemerkungen, St. Petersburg 1869.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/20\">",
"      Roos DB. Congenital anomalies associated with thoracic outlet syndrome. Anatomy, symptoms, diagnosis, and treatment. Am J Surg 1976; 132:771.",
"     </a>",
"    </li>",
"    <li>",
"     Bergman R, Thompson S, Afifi A. Catalog of Human Variation, Urban &amp; Schwarzenberg, Baltimore 1984. p.201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/22\">",
"      Pollack EW. Surgical anatomy of the thoracic outlet syndrome. Surg Gynecol Obstet 1980; 150:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/23\">",
"      Sanders RJ, Hammond SL. Management of cervical ribs and anomalous first ribs causing neurogenic thoracic outlet syndrome. J Vasc Surg 2002; 36:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/24\">",
"      Machleder HI, Moll F, Verity MA. The anterior scalene muscle in thoracic outlet compression syndrome. Histochemical and morphometric studies. Arch Surg 1986; 121:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/25\">",
"      Sanders RJ, Jackson CG, Banchero N, Pearce WH. Scalene muscle abnormalities in traumatic thoracic outlet syndrome. Am J Surg 1990; 159:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/26\">",
"      Casbas L, Chauffour X, Cau J, et al. Post-traumatic thoracic outlet syndromes. Ann Vasc Surg 2005; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/27\">",
"      Almeida DF, Meyer RD, Oh SJ. True neurogenic thoracic outlet syndrome in a competitive swimmer: a case report of this rare association. Arq Neuropsiquiatr 2007; 65:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/28\">",
"      Katirji B, Hardy RW Jr. Classic neurogenic thoracic outlet syndrome in a competitive swimmer: a true scalenus anticus syndrome. Muscle Nerve 1995; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/29\">",
"      Stapleton C, Herrington L, George K. Sonographic evaluation of the subclavian artery during thoracic outlet syndrome shoulder manoeuvres. Man Ther 2009; 14:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/30\">",
"      Lee TS, Hines GL. Cerebral embolic stroke and arm ischemia in a teenager with arterial thoracic outlet syndrome: a case report. Vasc Endovascular Surg 2007; 41:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/31\">",
"      Brooke BS, Freischlag JA. Contemporary management of thoracic outlet syndrome. Curr Opin Cardiol 2010; 25:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/32\">",
"      Jordan SE, Machleder HI. Diagnosis of thoracic outlet syndrome using electrophysiologically guided anterior scalene blocks. Ann Vasc Surg 1998; 12:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/33\">",
"      Baxter GM, Kincaid W, Jeffrey RF, et al. Comparison of colour Doppler ultrasound with venography in the diagnosis of axillary and subclavian vein thrombosis. Br J Radiol 1991; 64:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/34\">",
"      Passman MA, Criado E, Farber MA, et al. Efficacy of color flow duplex imaging for proximal upper extremity venous outflow obstruction in hemodialysis patients. J Vasc Surg 1998; 28:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/35\">",
"      Roos DB. Historical perspectives and anatomic considerations. Thoracic outlet syndrome. Semin Thorac Cardiovasc Surg 1996; 8:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/36\">",
"      Cuetter AC, Bartoszek DM. The thoracic outlet syndrome: controversies, overdiagnosis, overtreatment, and recommendations for management. Muscle Nerve 1989; 12:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/37\">",
"      Tilney ML, Griffiths HJ, Edwards EA. Natural history of major venous thrombosis of the upper extremity. Arch Surg 1970; 101:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/38\">",
"      Urschel HC Jr, Razzuk MA. Paget-Schroetter syndrome: what is the best management? Ann Thorac Surg 2000; 69:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/39\">",
"      Lee JT, Karwowski JK, Harris EJ, et al. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg 2006; 43:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/40\">",
"      Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. J Vasc Surg 2007; 45:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/41\">",
"      Schneider DB, Dimuzio PJ, Martin ND, et al. Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty. J Vasc Surg 2004; 40:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/42\">",
"      Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein. J Vasc Surg 1993; 17:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/43\">",
"      Urschel HC Jr, Razzuk MA. Improved management of the Paget-Schroetter syndrome secondary to thoracic outlet compression. Ann Thorac Surg 1991; 52:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/44\">",
"      Coote, H. Exostosis of the left transverse process of the seventh cervical vertebra, surrounded by blood vessels and nerves; successful removal. Lancet 1861; 1:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/45\">",
"      Adson AW, Coffey JR. CERVICAL RIB: A METHOD OF ANTERIOR APPROACH FOR RELIEF OF SYMPTOMS BY DIVISION OF THE SCALENUS ANTICUS. Ann Surg 1927; 85:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/46\">",
"      CLAGETT OT. Research and prosearch. J Thorac Cardiovasc Surg 1962; 44:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/47\">",
"      Roos DB. Transaxillary approach for first rib resection to relieve thoracic outlet syndrome. Ann Surg 1966; 163:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/48\">",
"      Gol A, Patrick DW, McNeel DP. Relief of costoclavicular syndrome by infraclavicular removal of first rib. Technical note. J Neurosurg 1968; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/49\">",
"      Le Forestier N, Mouton P, Maisonobe T, et al. [True neurological thoracic outlet syndrome]. Rev Neurol (Paris) 2000; 156:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/50\">",
"      Le Forestier N, Moulonguet A, Maisonobe T, et al. True neurogenic thoracic outlet syndrome: electrophysiological diagnosis in six cases. Muscle Nerve 1998; 21:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/51\">",
"      Wilbourn AJ. Thoracic outlet syndrome surgery causing severe brachial plexopathy. Muscle Nerve 1988; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/52\">",
"      Dale WA. Thoracic outlet compression syndrome. Critique in 1982. Arch Surg 1982; 117:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/53\">",
"      Sanders RJ. Results of the surgical treatment for thoracic outlet syndrome. Semin Thorac Cardiovasc Surg 1996; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/54\">",
"      Sanders RJ, Monsour JW, Gerber WF, et al. Scalenectomy versus first rib resection for treatment of the thoracic outlet syndrome. Surgery 1979; 85:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/55\">",
"      Sanders RJ, Pearce WH. The treatment of thoracic outlet syndrome: a comparison of different operations. J Vasc Surg 1989; 10:626.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders RJ, Haug CE. Thoracic Outlet Syndrome: A Common Sequela of Neck Injuries, Lippincott, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/57\">",
"      Axelrod DA, Proctor MC, Geisser ME, et al. Outcomes after surgery for thoracic outlet syndrome. J Vasc Surg 2001; 33:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/58\">",
"      Franklin GM, Fulton-Kehoe D, Bradley C, Smith-Weller T. Outcome of surgery for thoracic outlet syndrome in Washington state workers' compensation. Neurology 2000; 54:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3177/abstract/59\">",
"      Jordan SE, Ahn SS, Gelabert HA. Differentiation of thoracic outlet syndrome from treatment-resistant cervical brachial pain syndromes: development and utilization of a questionnaire, clinical examination and ultrasound evaluation. Pain Physician 2007; 10:441.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15208 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3177=[""].join("\n");
var outline_f3_6_3177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H293627611\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455545309\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455545323\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455545331\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293627701\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455545366\">",
"      True neurogenic TOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488964654\">",
"      Disputed neurogenic TOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455545401\">",
"      Venous TOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455545436\">",
"      Arterial TOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293628070\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293628493\">",
"      Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293629306\">",
"      Physiologic vascular studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293627869\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293628520\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293628803\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293628810\">",
"      Anticoagulation/thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293631715\">",
"      Managing ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293625095\">",
"      THORACIC OUTLET DECOMPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293631442\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293627619\">",
"      Approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293627199\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293627611\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15208|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/58/18338\" title=\"figure 1\">",
"      Anatomy of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/46/39650\" title=\"figure 2\">",
"      Cervical rib causing thoracic outlet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/19/22836\" title=\"figure 3\">",
"      Thoracic dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/1/18454\" title=\"figure 4\">",
"      Collateral circulation around the shoulder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=related_link\">",
"      Overview of upper extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_6_3178="Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients";
var content_f3_6_3178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Martin Zamora, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/6/3178/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/6/3178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H709584814\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV), a member of the betaherpesvirus group, remains an important cause of morbidity and mortality in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the second most common infection among lung transplant recipients, after bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the development and availability of potent antiviral agents has decreased CMV-related mortality, there is a growing body of evidence that the indirect effects of CMV may be equally important or even more important than its direct effects of tissue injury and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/3\">",
"     3",
"    </a>",
"    ]. CMV-induced immunosuppression may lead to infection with other opportunistic organisms. In addition, CMV infection and disease have been associated with acute and chronic rejection (bronchiolitis obliterans syndrome) in some, but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to the diagnosis and treatment of CMV infections in lung transplant recipients continues to evolve as transplant specialists gain experience using molecular diagnostic techniques and the potent oral antiviral agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    . The epidemiology, clinical features, diagnosis, and treatment of CMV infection in lung transplant recipients will be discussed here. Prevention of CMV infection in lung transplant recipients, as well as infectious complications due to pathogens other than CMV, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H410319\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cytomegalovirus (CMV) infection is acquired through close physical contact involving direct inoculation with infected cells or body fluids. Following primary infection, CMV infection persists for life. Population studies document a gradual increase in CMV seropositivity through young adulthood. Although there is considerable variability, more than one-half of adults in the United States have serologic evidence of previous infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMV infection following transplantation can be acquired in one of several ways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      By transmission with the donor organ from a CMV-seropositive donor",
"     </li>",
"     <li>",
"      By transfusion of blood products from a CMV-seropositive blood donor",
"     </li>",
"     <li>",
"      By reactivation of latent infection in a seropositive recipient",
"     </li>",
"     <li>",
"      By close physical contact with a CMV-infected individual",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588818\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of cytomegalovirus (CMV) in solid organ transplantation were published by the American Society of Transplantation in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/7\">",
"     7",
"    </a>",
"    ], and by the Transplantation Society International CMV Consensus Group in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, recommendations for the management of CMV infection in lung transplant recipients were published in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/9\">",
"     9",
"    </a>",
"    ]. The following discussion and recommendations are consistent with these documents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588825\">",
"    <span class=\"h1\">",
"     INFECTION VERSUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV infection and disease are not synonymous terms; not all patients with infection develop overt clinical disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMV infection is defined as evidence of CMV replication regardless of symptoms or signs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H709584842\">",
"       'Diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      CMV disease is defined as evidence of CMV infection with attributable symptoms or signs; CMV disease may manifest as either a viral syndrome (eg, fever, malaise, leukopenia, thrombocytopenia) or as tissue invasive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H709584835\">",
"       'Clinical features'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709584835\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) infection in the lung transplant recipient may range from asymptomatic viremia (CMV infection) to CMV disease manifested as a viral syndrome or as tissue invasive disease, most commonly pneumonitis. (See",
"    <a class=\"local\" href=\"#H709588825\">",
"     'Infection versus disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presentation of CMV infection and rejection can be similar, but the timing of presentation in relation to transplantation may help to differentiate them. CMV infection is rarely detected before the second week after transplantation, and the mean times to the first detection of viremia and to the initial episode of CMV pneumonitis are approximately 40 and 55 days, respectively, in patients not receiving prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/11\">",
"     11",
"    </a>",
"    ]. In comparison, acute rejection has a variable time course, but it may occur in the early post-transplant setting when CMV infection would not be expected.",
"   </p>",
"   <p>",
"    Although CMV disease occurs most commonly during the first three months following transplantation in patients not receiving prophylaxis, in patients receiving CMV prophylaxis, CMV disease typically occurs during the first three months after discontinuing CMV prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588841\">",
"    <span class=\"h2\">",
"     CMV syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a CMV syndrome have evidence of clinical disease, but without end-organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/10\">",
"     10",
"    </a>",
"    ]. Typical symptoms include fever, malaise, weakness, myalgias, and arthralgias. Many patients have leukopenia and thrombocytopenia that occur in the setting of viremia. (See",
"    <a class=\"local\" href=\"#H695016\">",
"     'CMV replication assays'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588848\">",
"    <span class=\"h2\">",
"     Tissue invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis is the most common presentation of tissue invasive CMV disease following lung transplantation, although other manifestations such as hepatitis, gastroenteritis, and colitis can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Pneumonitis poses a dilemma, because its clinical features are easily confused with acute rejection. Both groups of patients may present with low-grade fever, shortness of breath, nonproductive cough, and changes in measured pulmonary function. The timing of presentation can help to distinguish these processes from one another, as discussed above. (See",
"    <a class=\"local\" href=\"#H709584835\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    CMV pneumonitis has been associated with a variety of radiographic findings, including patchy or diffuse ground-glass opacities, patchy consolidation, small nodular opacities, or a combination of these features (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50696 \" href=\"UTD.htm?38/17/39185\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65546 \" href=\"UTD.htm?4/10/4266\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Less common findings include thickened bronchovascular bundles, tree-in-bud airway pattern, reticular opacities, and small pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588855\">",
"    <span class=\"h2\">",
"     Indirect effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the direct effects of CMV infection and disease, CMV has been associated with chronic rejection (bronchiolitis obliterans syndrome) in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/3-6,12,17,18\">",
"     3-6,12,17,18",
"    </a>",
"    ]. In one study, treated CMV pneumonitis that developed during the first six months after transplantation increased the risk for bronchiolitis obliterans syndrome (hazard ratio [HR], 2.19; 95% CI, 1.36-3.51) and post-transplantation death (HR 1.89; 95% CI 1.11-3.23) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/18\">",
"     18",
"    </a>",
"    ]. In another study, the use of CMV prophylaxis resulted in a significant decrease in the rate of bronchiolitis obliterans syndrome following lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMV has also been associated with acute rejection in renal and liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunomodulatory effects of CMV may predispose patients to several opportunistic infections, including those caused by Aspergillus species, Pneumocystis jirovecii, Nocardia species, HHV-6, HHV-7, and Epstein-Barr virus (EBV)-associated post-transplant-associated lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709584842\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate diagnostic tests are essential for the management of cytomegalovirus (CMV) following lung transplantation. Several diagnostic modalities are available including serology, hybrid capture assay, qualitative and quantitative polymerase chain reaction, pp65 antigenemia, culture, and histopathology. The techniques for detecting CMV replication (CMV viral load and CMV pp65 antigenemia) have improved considerably in recent years.",
"   </p>",
"   <p>",
"    Patients in whom CMV infection or disease is suspected should undergo testing of the blood for CMV replication. In addition to testing for CMV replication in the peripheral blood, patients suspected of having invasive disease, such as pneumonitis, should undergo bronchoscopy with transbronchial lung biopsy, as discussed below. (See",
"    <a class=\"local\" href=\"#H709588897\">",
"     'Histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The choice of test to detect CMV replication in the peripheral blood varies by transplant center. Both viral load testing (using polymerase chain reaction [PCR] or the hybrid capture assay) and antigenemia testing are acceptable methods, although PCR is used more commonly. We favor using a whole blood, quantitative PCR-based assay. Once a specific assay and type of specimen has been used in a given patient, the same methods should be used for subsequent monitoring given the lack of standardization of various assays and differences in results based on specimen type. In patients who are being treated for CMV infection or disease, testing for CMV detection should be repeated weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709584849\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recipient should be tested for CMV antibodies prior to transplantation, and the donor should be tested before or at the time of transplantation in order to ascertain the need for postoperative prophylaxis. Only CMV IgG should be tested, rather than IgM or a combination of IgM and IgG, since false positive IgM results might reduce the specificity of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,22-24\">",
"     8,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology should",
"    <strong>",
"     not",
"    </strong>",
"    be used to diagnose active CMV infection or disease in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695016\">",
"    <span class=\"h2\">",
"     CMV replication assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for CMV replication include CMV quantitative PCR (viral load) assays and CMV pp65 antigenemia. The use of these tests for the prevention of CMV disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link&amp;anchor=H695482#H695482\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\", section on 'CMV replication assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588883\">",
"    <span class=\"h3\">",
"     CMV viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV viral load testing using PCR techniques or hybrid capture assays can detect and quantify small amounts of CMV DNA or DNA:RNA hybrids in clinical specimens, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. CMV viral load assays can be performed rapidly, particularly at centers that conduct testing in-house. Since results can vary substantially from laboratory to laboratory, it is important to use the same assay while monitoring an individual patient over time. In addition, CMV DNA is typically detected sooner and in greater amounts from whole blood compared with plasma, so a single specimen type should be used each time testing is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to using viral load assays for detecting viremia, these assays can also be performed on bronchoalveolar lavage (BAL) fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue specimens, and such testing has been advocated in the 2010 Transplantation Society International CMV Consensus Group [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,27-30\">",
"     8,27-30",
"    </a>",
"    ]. Some studies have suggested that the magnitude of the CMV viral load from BAL fluid correlates with pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/27,29\">",
"     27,29",
"    </a>",
"    ], although one study suggested that this assay is not able to discriminate between infection and invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588890\">",
"    <span class=\"h3\">",
"     CMV pp65 antigenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CMV pp65 antigenemia assay permits the rapid detection of CMV proteins in peripheral blood polymorphonuclear leukocytes using tagged monoclonal antibodies specific to the CMV pp65 lower matrix protein. Positive results are reported as the number of cells with staining per total number of cells counted. Results are generally available within 24 hours and the test performs well in solid organ transplant recipients; in these patients, antigenemia appears to correlate with viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/10\">",
"     10",
"    </a>",
"    ]. One limitation is that it may not be possible to use the CMV antigenemia assay when the absolute neutrophil count is less than 1000",
"    <span class=\"nowrap\">",
"     neutrophils/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of cytomegalovirus\", section on 'CMV antigenemia assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695169\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of the results of the viral load and antigenemia assays are problematic for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neither the CMV viral load assays nor the antigenemia assays have been standardized, so it is not possible to define cutoff values that are considered significant for all institutions. For this reason, each transplant center must define and validate cutoff values internally.",
"     </li>",
"     <li>",
"      Viremia is associated with a broad spectrum of clinical disease, ranging from asymptomatic viral shedding to severe tissue-invasive disease. The implications of a positive assay depend largely upon the clinical context and the source of the specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some cases of tissue-invasive disease, particularly with gastrointestinal and retinal disease, there may not be evidence of CMV replication in the peripheral blood [",
"      <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694915\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of CMV from culture of BAL fluid can be used to help diagnose active infection. However, shedding of CMV from the lungs can occur even in the absence of invasive disease, so a positive culture must be interpreted in the context of the specific clinical circumstances.",
"   </p>",
"   <p>",
"    The conventional tube culture, which can take weeks, has largely been replaced by the rapid shell-vial culture technique, which can be processed in 24 to 48 hours. Unlike conventional culture, the shell-vial technique does not depend upon the development of a cytopathic effect in tissue culture. Instead, a fluorescence tagged monoclonal antibody is used to detect a CMV antigen expressed early in viral replication. Similar antibody tests for rapid detection of CMV antigens in infected cells (antigen assays) can be applied to BAL fluid or blood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588897\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiberoptic bronchoscopy with transbronchial lung biopsy is a safe, reliable diagnostic approach with good sensitivity, and is the preferred method for the diagnosis of CMV pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Occasionally, the histologic features of infection and rejection overlap, but usually the two conditions can be distinguished [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Although the definitive diagnosis of CMV pneumonitis requires the demonstration of characteristic inclusion bodies in a lung biopsy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65546 \" href=\"UTD.htm?4/10/4266\">",
"     image 2",
"    </a>",
"    ), bronchial washing, or BAL fluid, a presumptive diagnosis can be made based upon a positive culture and a compatible clinical picture, provided that other causes have been excluded. Viral antigens can be detected in tissue using immunohistochemistry or in situ DNA hybridization, and such methods should be performed routinely on biopsy specimens to maximize sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709584933\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACTIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of active disease depends on the specific clinical circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Our recommendations are consistent with the various guidelines described above, particularly those published in 2010 by the Transplantation Society International CMV Consensus Group [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H709588818\">",
"     'Guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    has traditionally been the drug of choice for the treatment of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12,40,41\">",
"     12,40,41",
"    </a>",
"    ], the development of the highly bioavailable prodrug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , has provided an oral option for the treatment of non-severe CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,42\">",
"     8,42",
"    </a>",
"    ]. Ganciclovir remains the drug of choice for children, as well as for adults with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to give appropriate doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , since inadequate dosing may reduce efficacy and lead to resistance, whereas supratherapeutic dosing may lead to toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,43,44\">",
"     8,43,44",
"    </a>",
"    ]. Hematologic suppression, in particular neutropenia, appears to be the most significant and common adverse event associated with ganciclovir and valganciclovir. It is important to note, however, that CMV itself can also cause leukopenia and thrombocytopenia, and that these abnormalities often improve with antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link&amp;anchor=H6#H6\">",
"     \"Ganciclovir and valganciclovir: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used for the treatment of CMV infection or disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588918\">",
"    <span class=\"h2\">",
"     CMV viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All lung transplant recipients with a CMV syndrome, and many patients with asymptomatic CMV viremia, should receive antiviral therapy. The rationale for treating patients with asymptomatic CMV viremia is to prevent the development of invasive disease, as well as to prevent potential indirect effects of CMV viremia, such as rejection. However, there are no studies showing that the treatment of asymptomatic viremia decreases the incidence of bronchiolitis obliterans syndrome.",
"   </p>",
"   <p>",
"    The decision of when to start treatment depends on the threshold value of CMV viral load or antigenemia that is considered significant. Since the CMV viral load and antigenemia assays have not been standardized, cutoffs for initiating therapy must be determined at each institution. (See",
"    <a class=\"local\" href=\"#H709588855\">",
"     'Indirect effects'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H695016\">",
"     'CMV replication assays'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link&amp;anchor=H1635497496#H1635497496\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the treatment of asymptomatic or mildly symptomatic CMV viremia, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    900 mg twice daily has supplanted intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    as the drug of choice. Treatment should continue until the viral load becomes undetectable by a sensitive monitoring assay; testing during treatment is usually performed once or twice a week [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. Intravenous ganciclovir 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours should be substituted for valganciclovir in those who cannot take an oral regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588925\">",
"    <span class=\"h2\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of invasive disease depends upon the severity of illness. There is more accumulated experience with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    than with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    for the treatment of CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12\">",
"     12",
"    </a>",
"    ]. Either intravenous ganciclovir or oral valganciclovir can be used for the initial treatment of non-severe disease in adults, but only intravenous ganciclovir should be used in patients with severe disease and in children, in whom the safety and efficacy of oral valganciclovir is less well established than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240597688\">",
"    <span class=\"h3\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for lung transplant recipients with severe disease is based primarily upon data extrapolated from other patient populations, such as HIV-positive patients with CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/6,45-47\">",
"     6,45-47",
"    </a>",
"    ]. Adults with severe disease and children (regardless of disease severity) should be treated with intravenous ganciclovir 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, with dose adjustment for renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. Most lung transplant recipients with CMV pneumonitis have severe disease, but even the rare patient who presents with non-severe CMV pneumonitis should receive intravenous ganciclovir since the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has not been established in patients with CMV pneumonitis.",
"   </p>",
"   <p>",
"    The efficacy of antiviral treatment can be potentiated by reducing the intensity of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this approach may increase the risk of rejection, so must be done with caution.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    may be augmented by the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"     cytomegalovirus immune globulin",
"    </a>",
"    (CytoGam), although only limited data support the efficacy of this approach in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588932\">",
"    <span class=\"h3\">",
"     Non-severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    has traditionally been the drug of choice for the treatment of CMV disease, the development of the highly bioavailable prodrug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , has provided an oral option for the treatment of non-severe CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of either intravenous ganciclovir (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or oral valganciclovir (900 mg orally every 12 hours) is recommended in the 2010 International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation for the treatment of non-severe CMV disease in adult solid organ transplant recipients, including those with either CMV syndrome or invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. For patients with non-severe disease, we recommend oral valganciclovir rather than IV ganciclovir provided that the patient is expected to have adequate absorption of oral medications. For patients who are expected to have poor absorption of oral medications (eg, moderate to severe CMV gastrointestinal involvement with nausea and vomiting or diarrhea), we use IV ganciclovir at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours, with dose adjustment for renal insufficiency. All patients with CMV pneumonitis should be treated with intravenous ganciclovir, as discussed below. (See",
"    <a class=\"local\" href=\"#H240597688\">",
"     'Severe disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A randomized trial, called the Valcyte in CMV-disease Treatment of solid Organ Recipients (VICTOR) trial, demonstrated that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is non-inferior to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    in 321 solid organ transplant recipients with non-life-threatening CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients received either oral valganciclovir (900 mg twice daily) or intravenous ganciclovir (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice daily). Both groups continued therapy for 21 days before switching to valganciclovir 900 mg once daily for an additional 28 days. Forty-eight percent of patients had a CMV syndrome and 49 percent had CMV disease. Of note, only 6 percent of patients were lung transplant recipients, whereas 74 percent were renal transplant recipients. The primary endpoint was clearance of CMV viremia at day 21 of therapy, which was achieved in 45 percent of those receiving valganciclovir and 48 percent of those receiving ganciclovir. Clinical resolution of CMV disease was a secondary endpoint, and was achieved in 77 percent of those receiving valganciclovir and 80 percent of those receiving ganciclovir. One year following treatment, there were no differences in clinical or viral eradication of CMV disease or in incidence of ganciclovir resistance between the patients who received valganciclovir and those who received ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588946\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should continue to receive treatment doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    until resolution of viremia is documented, and for at least two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. An even longer course of therapy should be considered in patients with severe disease, as well as in those who are CMV IgG seronegative at the beginning of treatment and in those with a high baseline CMV viral load.",
"   </p>",
"   <p>",
"    Patients should be monitored weekly during therapy with an appropriate test of CMV replication from the blood. Resolution of viremia is proven with two consecutive negative CMV viral load assays, ideally drawn one week apart. (See",
"    <a class=\"local\" href=\"#H709584842\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Secondary suppression with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    900 mg once daily for one to three months may be given following completion of induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. The decision of whether secondary suppression is necessary and the duration depends on the particular circumstances; patients at increased risk for recurrence should receive the longest duration of suppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709588953\">",
"    <span class=\"h2\">",
"     Ganciclovir resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    resistance include prolonged antiviral use, ongoing active CMV replication, lack of prior CMV immunity (CMV",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/51\">",
"     51",
"    </a>",
"    ], and inadequate antiviral drug delivery (eg, treatment with oral ganciclovir) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"     8",
"    </a>",
"    ]. Resistance to ganciclovir should be considered in recipients who fail to improve after two weeks of adequate doses of antiviral therapy, or have frequent relapses or breakthrough CMV viremia or disease while on prophylaxis. In such patients, genotypic resistance testing should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,9,52-54\">",
"     8,9,52-54",
"    </a>",
"    ]. It should be noted, however, that the viral load may rise following initiation of therapy in some patients and does not necessarily signify ganciclovir resistance; this is especially common in stem cell transplant recipients, in whom rising viral loads more frequently represent higher immunosuppression rather than ganciclovir resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,55\">",
"     8,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , the most common mutations are UL97 phosphotransferase mutations, which confer resistance to ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,56\">",
"     8,56",
"    </a>",
"    ]. UL54 DNA polymerase mutations may occur as second-step mutations in patients who already have a UL97 mutation; UL54 mutations confer high-level ganciclovir resistance, as well as cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12,57-59\">",
"     12,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    -resistant CMV infection are limited to case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,60-63\">",
"     8,60-63",
"    </a>",
"    ]. In patients with suspected or proven ganciclovir-resistant CMV infection or disease, we typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , which is typically dosed at 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours (or 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours), with adjustment for renal dysfunction. It is important to note that nephrotoxicity is common when foscarnet is given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Electrolyte disturbances are also common with foscarnet. An alternative to foscarnet is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , but there is less clinical experience with this agent for treating resistant CMV infection, and its use is limited by the potential for severe nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients treated empirically for presumed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    -resistant CMV, the regimen should be adjusted as indicated based upon the results of genotypic resistance testing. Other approaches published in case reports and small case series have included a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    and ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/60\">",
"     60",
"    </a>",
"    ], and high-dose ganciclovir in patients with low-level ganciclovir resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/8,61\">",
"     8,61",
"    </a>",
"    ]. There has been interest in using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , an immunosuppressive agent with in vitro activity against CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], but further study is necessary before it can be recommended.",
"   </p>",
"   <p>",
"    An experimental agent, AIC246, which belongs to a novel class of 3,4-dihydroquinazolinyl acetic acids, was administered to a lung transplant recipient with multidrug-resistant disseminated CMV infection (viremia, pneumonitis, colitis, retinitis) in combination with reduced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/66\">",
"     66",
"    </a>",
"    ]. The patient experienced rapid clinical, virologic, and radiographic resolution of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720107\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV disease is associated with increased mortality rates among solid organ transplant recipients, and the use of antiviral prophylaxis against CMV is associated with a reduction in all-cause mortality after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/12,21,67-71\">",
"     12,21,67-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 231 lung transplant recipients, five-year survival was significantly higher in patients who did not develop CMV pneumonitis during the first six months following transplantation compared with those who were treated for CMV pneumonitis during the first six months (71 versus 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/6/3178/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22545072\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods to prevent CMV infection and disease, including universal prophylaxis and preemptive therapy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=see_link\">",
"     \"Patient information: Cytomegalovirus (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709584940\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in lung transplant recipients. (See",
"      <a class=\"local\" href=\"#H709584814\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for the management of CMV in solid organ transplantation were published by the American Society of Transplantation in 2009 and by the Transplantation Society International CMV Consensus Group in 2010. In addition, recommendations for the management of CMV infection in lung transplant recipients were published in 2005. (See",
"      <a class=\"local\" href=\"#H709588818\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV infection is defined as evidence of CMV replication regardless of symptoms or signs. (See",
"      <a class=\"local\" href=\"#H709588825\">",
"       'Infection versus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV disease is defined as evidence of CMV infection with attributable symptoms or signs; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia, or as tissue invasive disease. (See",
"      <a class=\"local\" href=\"#H709588825\">",
"       'Infection versus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spectrum of CMV infections range from asymptomatic viremia (CMV infection) to CMV disease manifested as a viral syndrome or as tissue invasive disease, most commonly pneumonitis. (See",
"      <a class=\"local\" href=\"#H709584835\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in whom CMV infection or disease is suspected should undergo testing of the blood for CMV replication. We favor using a whole blood, quantitative PCR-based assay. In addition to testing for CMV viremia in the peripheral blood, patients suspected of having invasive disease, such as pneumonitis, should undergo bronchoscopy with transbronchial lung biopsy. (See",
"      <a class=\"local\" href=\"#H709584842\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H709588897\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All lung transplant recipients with severe disease require antiviral therapy with an agent that has activity against CMV. We recommend that such patients be treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      rather than oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The dosing of ganciclovir is 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours, with dose adjustment for renal insufficiency. In addition to antiviral therapy, we suggest administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"       cytomegalovirus immune globulin",
"      </a>",
"      (CytoGam) to patients with severe disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H240597688\">",
"       'Severe disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with non-severe CMV infection or disease, we suggest anti-CMV treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is done to prevent progression to severe disease and to prevent the indirect effects of CMV. For such patients, we recommend oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      rather than IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      provided that the patient is expected to have adequate absorption of oral medications (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The dosing of valganciclovir is 900 mg orally twice daily, with dose adjustment for renal insufficiency. For patients who are expected to have poor absorption of oral medications (eg, moderate to severe CMV gastrointestinal involvement with nausea and vomiting or diarrhea), we use IV ganciclovir at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours, with dose adjustment for renal insufficiency. (See",
"      <a class=\"local\" href=\"#H709588918\">",
"       'CMV viremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H709588932\">",
"       'Non-severe disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      resistance, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Foscarnet should be dosed at 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours (or 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours). (See",
"      <a class=\"local\" href=\"#H709588953\">",
"       'Ganciclovir resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/1\">",
"      Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/2\">",
"      Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med 1979; 139:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/3\">",
"      Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/4\">",
"      Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/5\">",
"      Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/6\">",
"      Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/7\">",
"      Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/8\">",
"      Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/9\">",
"      Zamora MR, Davis RD, Leonard C, CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/10\">",
"      Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/11\">",
"      Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017.",
"     </a>",
"    </li>",
"    <li>",
"     Razonable, RR, Limaye, RR. Cytomegalovirus infection after solid organ transplantation. In: Transplant Infections, 3rd ed, Bowden, RA, Ljungman, P, Snydman, DR (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.328.",
"    </li>",
"    <li>",
"     Gavalda, J, Roman, A, Pahissa, A. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Transplant Infections, 3rd edition, Bowden, RA, Ljungman, P, Snydman, DR (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/14\">",
"      Franquet T, Lee KS, M&uuml;ller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol 2003; 181:1059.",
"     </a>",
"    </li>",
"    <li>",
"     Webb, WR, Muller, NL, Naidich, DP. Infections. In: High-resolution CT of the Lung, Lippincott Williams and Wilkins, Philadelphia 2009. p.415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/16\">",
"      Kang EY, Patz EF Jr, M&uuml;ller NL. Cytomegalovirus pneumonia in transplant patients: CT findings. J Comput Assist Tomogr 1996; 20:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/17\">",
"      Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/18\">",
"      Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/19\">",
"      Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/20\">",
"      Rosen HR, Corless CL, Rabkin J, Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 1998; 66:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/21\">",
"      Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/22\">",
"      Seed CR, Piscitelli LM, Maine GT, et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009; 49:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/23\">",
"      Weber B, Fall EM, Berger A, Doerr HW. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/24\">",
"      Lazzarotto T, Brojanac S, Maine GT, Landini MP. Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin Diagn Lab Immunol 1997; 4:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/25\">",
"      Barber L, Egan JJ, Lomax J, et al. A prospective study of a quantitative PCR ELISA assay for the diagnosis of CMV pneumonia in lung and heart-transplant recipients. J Heart Lung Transplant 2000; 19:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/26\">",
"      Bhorade SM, Sandesara C, Garrity ER, et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001; 20:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/27\">",
"      Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004; 42:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/28\">",
"      Riise GC, Andersson R, Bergstr&ouml;m T, et al. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 2000; 118:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/29\">",
"      Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/30\">",
"      Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009; 9:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/31\">",
"      Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996; 124:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/32\">",
"      Egan JJ, Barber L, Lomax J, et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995; 50:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/33\">",
"      Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/34\">",
"      Clelland C, Higenbottam T, Stewart S, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993; 147:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/35\">",
"      Paradis IL, Duncan SR, Dauber JH, et al. Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation. J Heart Lung Transplant 1992; 11:S232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/36\">",
"      Sibley RK, Berry GJ, Tazelaar HD, et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/37\">",
"      Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/38\">",
"      Tazelaar HD. Perivascular inflammation in pulmonary infections: implications for the diagnosis of lung rejection. J Heart Lung Transplant 1991; 10:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/39\">",
"      Nakhleh RE, Bolman RM 3rd, Henke CA, Hertz MI. Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomegaloviral infection. Am J Surg Pathol 1991; 15:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/40\">",
"      Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/41\">",
"      Sawyer MD, Mayoral JL, Gillingham KJ, et al. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 1993; 128:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/42\">",
"      Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/43\">",
"      Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/44\">",
"      McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/45\">",
"      Buhles WC Jr, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10 Suppl 3:S495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/46\">",
"      Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993; 168:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/47\">",
"      Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992; 326:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/48\">",
"      Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003; 22:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/49\">",
"      Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/50\">",
"      Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/51\">",
"      Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/52\">",
"      Kruger RM, Shannon WD, Arens MQ, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/53\">",
"      Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/54\">",
"      Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/55\">",
"      Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/56\">",
"      Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/57\">",
"      Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/58\">",
"      Chou S, Marousek GI, Van Wechel LC, et al. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/59\">",
"      Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/60\">",
"      Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/61\">",
"      West P, Schmiedeskamp M, Neeley H, et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl Infect Dis 2008; 10:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/62\">",
"      Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/63\">",
"      Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/64\">",
"      Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/65\">",
"      Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/66\">",
"      Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/67\">",
"      Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/68\">",
"      Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/69\">",
"      Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/70\">",
"      Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/6/3178/abstract/71\">",
"      Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15396 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3178=[""].join("\n");
var outline_f3_6_3178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H709584940\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709584814\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H410319\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709588818\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709588825\">",
"      INFECTION VERSUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709584835\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588841\">",
"      CMV syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588848\">",
"      Tissue invasive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588855\">",
"      Indirect effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709584842\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709584849\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695016\">",
"      CMV replication assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709588883\">",
"      - CMV viral load",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709588890\">",
"      - CMV pp65 antigenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H695169\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694915\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588897\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709584933\">",
"      TREATMENT OF ACTIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588918\">",
"      CMV viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588925\">",
"      Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H240597688\">",
"      - Severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709588932\">",
"      - Non-severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709588946\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709588953\">",
"      Ganciclovir resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H720107\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22545072\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709584940\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15396|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/17/39185\" title=\"diagnostic image 1\">",
"      CMV pneumonitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/10/4266\" title=\"diagnostic image 2\">",
"      CMV pneumonitis 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=related_link\">",
"      Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=related_link\">",
"      Patient information: Cytomegalovirus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_6_3179="Rx self-injurious behaviors";
var content_f3_6_3179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of self-injurious behaviors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Correct metabolic abnormalities",
"      </td>",
"      <td>",
"       Evaluate for somatic pain: ear, GI (constipation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Appropriate restricted diet: lactose, gluten",
"      </td>",
"      <td>",
"       Behavior modification program",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate for seizure activity",
"      </td>",
"      <td>",
"       Consistency and follow-through",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increase activity levels if under-aroused",
"      </td>",
"      <td>",
"       Protective gear: gloves, helmet",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce stimuli if over-aroused",
"      </td>",
"      <td>",
"       Appropriate use of medications",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3179=[""].join("\n");
var outline_f3_6_3179=null;
var title_f3_6_3180="DRI infants";
var content_f3_6_3180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary reference intakes of selected nutrients for infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        0 to 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        7 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate",
"       </td>",
"       <td>",
"        60 g/day",
"       </td>",
"       <td>",
"        95 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat",
"       </td>",
"       <td>",
"        31 g/day",
"       </td>",
"       <td>",
"        20 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein",
"       </td>",
"       <td>",
"        1.5 g/kg per day",
"       </td>",
"       <td>",
"        1 g/kg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        200 mg/day*",
"       </td>",
"       <td>",
"        260 mg/day*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        0.27 mg/day",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        11 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td>",
"        2 mg/day",
"       </td>",
"       <td>",
"        3 mg/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These values represent the Adequate Intake for calcium; there was insufficient scientific data to calculate a recommended dietary allowance (RDA).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The iron stores of full-term infants whose birth weight was appropriate for gestational age meet their iron requirement until four to six months of age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Committee on Nutrition American Academy of Pediatrics. Appendix J. Dietary Reference Intakes: Recommended Intakes for Individuals, Food and Nutrition Board, Institute of Medicine. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.1293.",
"      </li>",
"      <li>",
"       National Academies Press. Dietary Reference Intakes for Calcium and Vitamin D (2010). Available at file://books.nap.edu/openbook.php?record_id=13050&amp;page=291. Accessed on January 15, 2011.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3180=[""].join("\n");
var outline_f3_6_3180=null;
var title_f3_6_3181="Major interactions involving triazoles";
var content_f3_6_3181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major or life-threatening drug interactions involving triazoles*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on drug exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main clinical consequence of interaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Astemizole, bepridil, cisapride, halofantrine, pimozide, quinidine, sertindole, terfenadine",
"       </td>",
"       <td>",
"        Itraconazole, fluconazole, voriconazole, posaconazole&bull;",
"       </td>",
"       <td>",
"        &uarr; exposure to interacting drugs",
"       </td>",
"       <td>",
"        QT interval prolongation with risk of torsade de pointes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        &darr; exposure to voriconazole",
"       </td>",
"       <td>",
"        Treatment failure of voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Efavirenz",
"       </td>",
"       <td rowspan=\"2\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &darr; exposure to voriconazole",
"       </td>",
"       <td>",
"        Treatment failure of voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &uarr; exposure to efavirenz",
"       </td>",
"       <td>",
"        Risk of efavirenz toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ergot alkaloids",
"       </td>",
"       <td>",
"        Itraconazole, fluconazole, voriconazole, posaconazole&bull;",
"       </td>",
"       <td>",
"        &uarr; exposure to ergot alkaloid",
"       </td>",
"       <td>",
"        Ergotism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lovastatin, simvastatin",
"       </td>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        &uarr; exposure to HMG-CoA reductase inhibitor",
"       </td>",
"       <td>",
"        Risk of rhabdomyolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam, triazolam",
"       </td>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        &uarr; exposure to benzodiazepine",
"       </td>",
"       <td>",
"        Sleepiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Rifabutin",
"       </td>",
"       <td rowspan=\"2\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &darr; exposure to voriconazole",
"       </td>",
"       <td>",
"        Treatment failure of voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &uarr; exposure to rifabutin",
"       </td>",
"       <td>",
"        Uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampicin (rifampin)",
"       </td>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        &darr; exposure to voriconazole",
"       </td>",
"       <td>",
"        Treatment failure of voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-dose ritonavir (400 mg twice daily)",
"       </td>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        &darr; exposure to voriconazole",
"       </td>",
"       <td>",
"        Treatment failure of voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine-vinblastine",
"       </td>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        &uarr; exposure to vinca alkaloids",
"       </td>",
"       <td>",
"        Neurotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sirolimus",
"       </td>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        &uarr; exposure to sirolimus",
"       </td>",
"       <td>",
"        Risk of sirolimus toxicity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &uarr; indicates increased; &darr; indicates decreased.",
"     <br>",
"      * Triazoles include fluconazole, itraconazole, voriconazole, and posaconazole.",
"      <br>",
"       &bull;&nbsp;Where an interaction has been reported for one triazole, the contraindication has been extended to all others.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Nivoix, Y, Leveque, D, Herbrecht, R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3181=[""].join("\n");
var outline_f3_6_3181=null;
var title_f3_6_3182="Survival after lung transplant";
var content_f3_6_3182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Improved survival after lung transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival by era for adult lung transplants performed between January 1988 and June 2010. Conditional half-life is the time to 50 percent survival for the sub-set of recipients who were alive one year after transplantation.",
"    <div class=\"footnotes\">",
"     NA: not available.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Christie JD, Edwards LB, Kucheryavaya AY, et al. International Society of Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"     <br>",
"      For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled&nbsp;\"Adult&nbsp;Lung Transplants: Kaplan-Meier Survival by Era\"&nbsp;at:",
"      <a href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" style=\"FONT-STYLE: italic\">",
"       file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3182=[""].join("\n");
var outline_f3_6_3182=null;
var title_f3_6_3183="Uncommon causes pneumonia";
var content_f3_6_3183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common etiologic agents of pediatric pneumonia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microbial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Susceptible hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        (typeable and non-typeable)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Moraxella catarrhalis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"        (often group Y)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Klebsiella",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Enterobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Burkholderia cepacia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Achromobacter xylosoxidans",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Stenotrophomonas maltophilia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Legionella pneumophila",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas pseudomallei",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Francisella tularensis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (rabbits) or insect vector; bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella abortus",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (cattle, goats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila psittaci",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (parakeets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Leptospira",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Yersinia pestis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir or insect vector (rats); bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaerobic mouth flora (",
"        <em>",
"         Prevotella",
"        </em>",
"        spp., Fusobacterium,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp.)",
"       </td>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, contact with known TB, homeless, recent immigrants from endemic areas, prisoners, and HIV-infected individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nontuberculous mycobacterium",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Bordetella pertussis",
"        </em>",
"       </td>",
"       <td>",
"        Infants, exposure to adult with a cough illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        (typeable and non-typeable)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Moraxella catarrhalis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"        (often group Y)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Klebsiella",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Enterobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Burkholderia cepacia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Achromobacter xylosoxidans",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Stenotrophomonas maltophilia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Legionella pneumophila",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas pseudomallei",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Francisella tularensis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (rabbits) or insect vector; bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella abortus",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (cattle, goats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila psittaci",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (parakeets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Leptospira",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Yersinia pestis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir or insect vector (rats); bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaerobic mouth flora (",
"        <em>",
"         Prevotella",
"        </em>",
"        spp., Fusobacterium,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp.)",
"       </td>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, contact with known TB, homeless, recent immigrants from endemic areas, prisoners, and HIV-infected individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nontuberculous mycobacterium",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Bordetella pertussis",
"        </em>",
"       </td>",
"       <td>",
"        Infants, exposure to adult with a cough illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Coccidioides immitis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (southwest United States)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Histoplasma capsulatum",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (Ohio and Mississippi River valley)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Blastomyces dermatitidis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (Ohio and Mississippi River valley)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Candida",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Nosocomial pathogen, immunocompromised hosts, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Aspergillus",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Nosocomial pathogen, immunocompromised hosts, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pneumocystis jiroveci",
"        </em>",
"        (formerly",
"        <em>",
"         carinii",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Rickettsiae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Coxiella burnetii",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (sheep)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular insect vector",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubeola",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Immunocompromised hosts, first 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coronavirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterovirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubella",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hantavirus",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, exposure to a particular animal reservoir (mouse droppings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bocavirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parechovirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avian influenza",
"       </td>",
"       <td>",
"        Exposure to birds; travel to affected area",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding neonatal pneumonia (in infants &lt;28 days of age).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klein JO, Bacterial pneumonias, In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, McIntosh K, N Engl J Med 2002; 346:429, Gaston B, Pediatr Rev 2002; 23:132, Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, Feigin BD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, and Sandora T, Harper MB. Pediatr Clin North Am 2005; 52:1059.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_6_3183=[""].join("\n");
var outline_f3_6_3183=null;
